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SUMMARY
In this study, flunixin meglumine, 1.1 mg/kg, was administered intravenously to two 
groups o f dogs undergoing routine anaesthesia and surgery. The first group o f dogs 
(Group A), were given the drug during anaesthesia, prior to the start o f surgery, while the 
second group o f dogs (Group B), were given the drug immediately on termination o f  
anaesthesia and surgery. A pharmacokinetic study was undertaken to determine the 
presence o f any alterations in the kinetics o f flunixin, between the two groups o f dogs. The 
results obtained in this study indicated that the time o f administration o f flunixin to the 
anaesthetised dog had no effect on the pharmacokinetic parameters measured. There was 
no significant difference between the elimination half-lives (7.86 + 1.18 hours; 6.10 + 0.74 
hours), mean residence time (8.73 + 2.53 hours; 4.52 + 0.36 hours), or body clearance 
(34.88 + 5.64 ml/kg.hr; 34.55 + 4.58 ml/kg.hr) o f the drug, between these two groups o f  
dogs.
However, when the results o f this study were compared with the results o f other workers 
(Hardie et al, 1985; McKellar et al, 1991b), who had investigated the pharmacokinetics o f  
flunixin in the conscious dog, differences in the pharmacokinetics o f flunixin were found to 
exist. In this trial, the distribution and elimination half-lives obtained in anaesthetised dogs 
were double that obtained in conscious dogs by Hardie et al (1985) and McKellar et al 
(1991b). Also, the body clearance o f the drug in the anaesthetised dog was found to be 
half that in the conscious dog (Hardie et al, 1985; McKellar et al, 1991b). Ideally during 
this trial a parallel study in conscious dogs should have been undertaken simultaneously, to 
clarify that the distribution and elimination half-lives obtained in the anaesthetised dogs 
were indeed double that in the conscious dog.
There was no correlation between mean arterial blood pressure and any pharmacokinetic 
parameter.
Each individual dog was screened for evidence o f renal damage using biochemical markers 
and the results were compared with a third group o f dogs (Group C), who had undergone 
routine anaesthesia and surgery, but had not received flunixin. Flunixin meglumine caused 
a significant rise in BUN levels in dogs in the trial, when administered during anaesthesia. 
Thus, some renal damage occurred, irrespective o f whether the drug was administered to 
the anaesthetised animal prior to the start o f surgery or immediately on termination of
9
anaesthesia, and this occured in some cases, despite mean arterial blood pressure readings 
being within the normal range. The rise in BUN took place during the first 12 hours of 
flunixin administration in the anaesthetised dog, and in 75% o f the cases, was seen to be 
resolving within 30 hours o f its administration. In all cases, renal damage was not 
considered severe and did not produce any clinical signs except in one dog, which 
remained polydipsic for 2 months after anaesthesia. The study demonstrated, however, 
that the rise in BUN produced when flunixin was administered during anaesthesia, prior to 
the start o f surgery, was greater than that produced when the drug was given immediately 
on termination o f anaesthesia. This was demonstrated by a significant difference still 
existing in BUN levels, from 0 to 30 hours, between dogs in group A and control group C, 
while no significant difference existed in BUN levels from 0 to 30 hours between dogs in 
group B and control group C.
10
1. INTRODUCTION
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1.1 PAIN
Pain is an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage (Merskey, 1979); a definition which was adopted by the 'International 
Association for the study o f pain1 in 1986. Although most vertebrate species appear 
capable o f perceiving pain because they possess appropriate central and peripheral neural 
pathways, neurotransmitters and receptors (Kitchell and Erickson, 1983), the exact 
mechanisms o f pain are poorly understood.
Tissue damage can be caused by trauma and surgery, as well as by exposure to metabolic, 
bacterial or viral diseases and toxins. However, irrespective o f the aetiology o f the tissue 
damage or the tissues involved, the resulting inflammatory process is identical. Although 
the cardinal signs o f inflammation were described as early as 1650 B.C., it was not until this 
century that the presence o f histamine release at the site o f tissue injury demonstrated that, 
just as nerve impulses are transmitted by released chemicals, so are the signs o f  
inflammation caused by released chemical mediators (Lewis and Grant, 1924).
The physiology o f pain has been reviewed in detail by Kitchell and Erickson (1983). 
Briefly, when damage to tissues occurs, perception o f pain associated with this process 
depends upon the activation o f a discrete set o f pain receptors called nociceptors. 
Nociceptors are found in all body tissues, but are particularly numerous in the skin and 
internal tissues, such as the periosteum, joint capsule, arterial wall, muscles, tendons, and 
tentorium of the cranial vault (Lasagna, 1986). Once nociceptors are activated, they 
convert the noxious stimuli into nerve impulses, which are transmitted along afferent nerve 
fibres to synapse in the dorsal hom o f the spinal cord. The mechanism o f  this activation 
(transduction) is not fully understood. However, studies o f nociceptive transduction, have 
indicated that chemical mediators, synthesized and/or released in response to tissue 
damage, are responsible for the initiation o f specific sensory impulses. These sensory 
impulses in turn activate neurons in the lateral spinothalmic tract, which then convey the 
impulse to the thalamus and from the thalamus to the cerebral cortex in the brain, to evoke 
the sensation o f pain (figure 1).
The sensation o f pain can be controlled by pharmacological intervention at numerous sites 
within the relay systems responsible for carrying the appropriate sensory impulse to the 
brain (Besson and Chauoch, 1987; Mohrland, 1982). Analgesics are, therefore, often 
classified according to their site o f action into centrally-acting analgesics e.g. the opioids
12
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which act at selective receptors in the CNS as well as in other tissues (Martin, 1984; 
Lefebvre, 1986), and peripherally-acting analgesics which block the generation o f painful 
impulses by inhibiting or modifying excitation o f nociceptors (Jenkins, 1987). The non­
steroidal anti-inflammatory drugs (NSAIDs) represent the largest group o f peripherally 
acting analgesics. Until recently, the distinction between these two classes o f drug
had been fairly clear. However Ferreira and Nakamura in 1979, demonstrated that opioids 
have peripheral analgesic effects, while NSAIDs have been shown to have a powerful 
central analgesic action (Malmberg and Yaksh, 1992).
Plants rich in salicylic acid, the progenitor o f NSAIDs, were among the earliest 
components of herbal therapy, and were almost universally used as antipyretics and 
antirheumatics. Notable physicians such as Hippocrates, Pliny, Elder, and Celsus all 
recorded the beneficial effects o f these plants in the treatment o f ailments such as gout, 
fever, sciatica and earaches. However with the collapse o f the Roman empire, rational 
herbal therapy was lost for more than 1000 years to the literate world (Roueche', 1958). 
In 1763, Reverend E. Stone discovered that a herb containg salicylates (Willow bark) was 
being used to treat malarial fevers and chills in the folk medicine o f the English 
countryside. He reintroduced the willow's antipyretic powers to an emerging scientific 
community. A century later, Kolbe manufactured synthetic salicylic acid (Roueche', 1958). 
In 1899, the most famous descendent o f salicylic acid, acetylsalicylic acid (Aspirin) was 
marketed. It rapidly became the most widely used drug in the world (Roueche', 1958; 
Sneader, 1985). However because o f its widespread use, aspirin's toxic effects became 
apparent (Hart et al, 1979; Roth, 1985). Efforts to improve upon the side effects o f aspirin 
led to the development o f many more drugs o f this type.
In human medicine, approximately 40 NSAIDs have been licensed for use in the U K  By 
comparison, fewer agents are available with veterinary product licences. These drugs have 
been the mainstay o f treatment for the low grade chronic pain which occurs in conditions 
such as osteoarthritis, whereas the narcotic analgesics have been considered as the drugs 
of choice for acute pain. However, recent years have seen a revival o f interest in the use of 
NSAIDs, both in human and veterinary medicine, for the treatment o f  acute pain 
associated with trauma or surgery. In 1991, Reid and Nolan showed that the NSAID 
flunixin meglumine is as effective an analgesic as the opioid agonist, papavertum, in the 
treatment o f post-surgical pain in the dog. In humans, NSAIDs such as diclofenac, have
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been shown to be as effective as the opioids in controlling pain after hip surgery 
(Buchanan et al, 1988).
Recently, the importance o f the timing o f analgesia has been suggested to be o f potential 
major importance in the treatment o f post-operative pain (Wall, 1988; Woolf, 1989; W oolf
1991). Many experimental studies have been performed by human anaesthetists to 
determine whether acute pain behaviour or hyperexcitability o f dorsal horn neurons may 
be eliminated or reduced if  the afferent barrage is prevented from reaching the CNS by 
pre-injury neural blocks with local anaesthetics (Woolf and Wall, 1986b; Coderre and 
Melzack, 1987; Coderre et al, 1990), or if the excitability o f the CNS can be supressed 
before it receives a nociceptive input (Woolf and Wall, 1986a; Dickenson and Sullivan, 
1987). Other classes o f drugs which have been suggested as being potentially useful for 
this so called pre-emptive analgesia are the opioids and the NSAIDs. However, there is 
still no firm evidence that pre-emptive analgesia does lessen post-operative pain (Dahl and 
Kehlet, 1993) and better designed clinical studies, need to be performed before it is 
possible to definitively evaluate the clinical effectiveness o f the pre-emptive use o f 
analgesics (Dahl and Kehlet, 1993). At present, the prevention o f the functional changes in 
the central nervous system by pre-emptive analgesia or other techniques, is still a 
fascinating working hypothesis.
1.2 INFLAMMATION
Inflammation may be considered to be a series o f events which results from local tissue 
injury, and is mediated by vasoactive amines (histamine, serotonin), lymphokines, 
leukocyte products (enzymes, oxygen radicals), and the products o f arachidonic 
metabolism (eicosanoids). Other substances which assist in modulating the inflammatory 
process are kinins, complement and coagulation protein (Jenkins, 1987).
As a result o f local tissue injury, vasoactive substances are released from mast cells, white 
blood cells and local platelet aggregations. These substances give rise to pain, heat and 
swelling (Higgins and Lees, 1984). Sackman (1991) reviewed the inflammatory process in 
the following manner. There is relaxation o f the precapillary sphincter and the arterioles, 
venules and lymphatics dilate, causing the capillary beds to leak, pilling plasma into the 
intestitial pace. This exudation o f fluid and the subsequent swelling give rise to pain by 
exerting pressure on the local nerve endings. Kinins maintain the plasma transudation from 
the capillaries while bradykinin causes hyperalgesia and further loss o f vascular integrity.
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Concurrent with these vascular changes occurring at the damaged tissue site, neutrophils 
and monocytes start migrating towards the injured tissue in response to local chemotactic 
factors. The phagocytic cells then ingest and destroy any foreign material present at the 
site o f injury, using enzymes and toxic oxygen radicals, thereby further generating pain 
(Conlon, 1988).
Products o f arachidonic acid metabolism are mediators o f inflammation. Phospholipase 
enzyme, activated in response to cell injury, causes the release o f arachidonic acid from 
phospholipids embedded in cell membranes (Boothe, 1984). Metabolism o f arachidonic 
acid proceeds in two directions: The enzyme cyclo-oxygenase, which is present in all cells 
except mature red blood cells, utilizes arachidonic acid as a substrate to form, first, the 
unstable cyclic endoperoxides PGG2  and PGH2, and then immediately, by the action o f  
further specific enzymes, the classical prostaglandins, such as PGE2? prostacyclin (PGI2) 
and thromboxanes A2 (TXA2) (Moncada and Vane, 1977). The enzyme lipoxygenase, 
located mainly in the lungs, platelets and white blood cells, catalyses the hydroxylation of  
the straight chained fatty acids to leukotrienes and related compounds (Samuelsson, 1987) 
(figure 2).
Eicosanoids (Derivatives of eicosatetraenoic acid):-
Eicosanoids, particularly prostaglandins, appear to have a major role in peripheral 
nociception, and may also be involved in the modulation o f the central neurotransmission 
of impulses, associated with pain perception (Moore, 1985). When prostaglandins are 
produced from cell membrane phospholipids after cellular injury, they bind to receptors on 
the sensory nerve endings facilitating the discharge o f impulses, thus intensifying pain. 
Prostaglandins appear to sensitize pain receptors to the effects o f various physical and 
chemical stimuli and to other inflammatory mediators such as bradykinin and histamine 
(Ferreira, 1986; Williams and Higgs, 1988). Ferreira (1986) has shown that prostaglandins 
increase the response frequency o f  the receptors to control stimuli, probably by lowering 
the normally high threshold o f  polymodal nociceptors associated with C-fibres. He 
observed that prostacyclin produced an immediate hyperalgesia o f short duration. 
Eicosanoids are not stored in cells. They are synthesized de novo as needed and are rapidly 
eliminated. The half-life o f most prostaglandins range from seconds to minutes (Goldyne, 
1987).
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Figure 2: Diagrammatic representation of the inflammatory mediators formed from 
archidonic acid and the possible sites of action o f NSAID's and steroids.
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1.3 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
NSAIDs are a heterogeneous group o f compounds, often chemically unrelated (although 
most o f them are organic acids), which share certain therapeutic actions and side effects 
(Verbeeck et al, 1983). They are classified into three principal classes o f agents: 
Carboxylic acid, enolic acid and others. The carboxylic acid group o f agents inhibit cyclo- 
oxygenase enzymes while the enolic acid group o f agents block endoperoxide isomerase.
A) The carboxylic acids include:
1) Salicylic acids and esters:------------------  Sodium salicylate
Acetyl salicylic acid (Aspirin)
2) Acetic acid
a) Phenylacetes:----------------------------- Diclofenac
Alclofenac
b) Indole-acetates:--------------------------  Indomethacin
Sulindac
3) Propionic acids:----------------------------- Ibuprofen
Naproxen
Ketoprofen
Carprofen
4) Fenamic Acid:--------------------------------  Mefenamic acid
Meclofenamic acid 
Tolfenamic acid
5) Ouinolones:------------------------------------ Cinchophen
B) The Enolic acids include
1) Pyrazolones:----------------------------------  Phenylbutazone
Oxyphenylbutazone
Dipyrone
Isopyrin
2) Oxicams:---------------------------------------  Piroxicam
Tenoxicam
Meloxicam
C) The others include
1) Nicotinic acid derivative:-----------------------  Flunixin meglumine
18
1.3.1. Mechanism of action of NSAIDs
NSAIDs probably share a common mechanism o f action. They are considered to exert 
their analgesic effects peripherally and their activity appears to be due to inhibition of 
prostaglandin synthesis by reversible or irreversible inhibition o f the cyclo-oxygenase 
enzyme system (Vane, 1971). Aspirin irreversibly inhibits the enzyme cyclo-oxygenase, 
and hence its effects are especially potent and long-lasting. Most acidic NSAIDs compete 
with arachidonic acid for the active site o f the cyclo-oxygenase enzyme and, unlike aspirin, 
reversibly inhibit cyclo-oxygenase (Ferriera and Vane, 1973).
NSAIDs also inhibit the vascular, and in certain instances, the cellular phases of 
inflammation (Strorm and Thomsen, 1990). Whereas the vascular effects o f  most NSAIDs 
in inflammation are largely accounted for by inhibition o f prostaglandin synthesis (Vane, 
1971), the mechanism invoved in inhibition o f phagocyte function is less firmly established 
(Abramson et al, 1984a,b).
1.3.2. Pharmacology of NSAIDs
NSAIDs share certain pharmacological actions, therapeutic uses and side effects.
Analgesia
They are usually accepted as being effective against pain associated with inflammation 
(Dubinsky et al, 1987). According to a review by Tobin et al, 1986, NSAIDs have no 
direct effect on pain perception, but they reduce hypersensitivity to pain, by virtue o f the 
fact that they inhibit prostaglandin production. The analgesia produced by NSAIDs varies 
from moderate to quite marked, depending on the particular drug and the clinical 
condition. In the treatment o f post-operative pain, NSAIDs can be as effective as, or more 
effective than opioid analgesics (Reid and Nolan, 1991; Nolan and Reid, 1993).
Anti-inflammatory action
Certain prostanoids (PGE2 and PGI2) are important mediators o f the vascular changes in 
inflammation (Ferreira et al, 1974; Jones, 1977). Inhibition o f their formation by NSAIDs 
markedly reduces, but does not abolish, prostanoid-dependent swelling, oedema, 
erythema, and hypersensitivity to pain in inflamed tissues (Tobin et al, 1986), and is 
therefore very useful for the treatment o f soft tissue swelling. In recent years, it has been 
recognised increasingly that NSAIDs possess other properties, which are likely to
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contribute to their anti-inflammatory action (Lee and Foster, 1992), such as free radical 
scavenging activity and inhibition of the release o f lysosomal enzymes. Other 
nonprostaglandin-related effects o f NSAIDs are inhibition o f neutrophil activation and 
aggregation, and inhibition o f superoxide anion generation by neutrophils (Brooks and 
Day, 1991).
Antipyretic action
Pyrogens induce the synthesis o f  prostaglandin E2 in the hypothalamus, which alters the 
set point o f temperature regulation and thereby acts as a powerful pyretic agent (Frey,
1992). NSAIDs inhibit both the generation o f prostaglandins in the CNS and the fever 
caused by the pyrogens, and are therefore anti-pyretic in their action (Moncada and Vane, 
1979).
Anti-thrombotic action
When platelets aggregate, they release thromboxane A2, a potent platelet aggregator. 
NSAIDs block the formation o f thromboxane A2j thus reducing thrombosis and 
haemostasis (Meyers et al, 1979). Aspirin acetylates platelets and inhibits cyclo-oxygenase 
for their life span, whereas the action o f the other NSAIDs is reversible and the effect is 
generally maximal at 3 hours and has worn off by 24 hours (Henry, 1988). An exception 
to this rule may be piroxicam which, because o f its long plasma half-life, appears to inhibit 
platelet function for at least 72 hours after dosing to steady state (McQueen et al, 1986).
1.3.3 Effect of NSAIDs on organ system s
In addition to sharing many therapeutic activities with respect to their anti-inflammatory, 
anti-pyretic and analgesic effects, NSAIDs also share many adverse effects (Sedor et al, 
1986), o f which those affecting the gastrointestinal and renal systems are the most 
commonly described. However toxicity differs markedly between species and from one 
NSAID to another (Mazue et al, 1983).
al Gastrointestinal
The most common side effects o f NSAIDs involve the gastrointestinal tract. Specific side 
effects and their severity vary between drugs but include vomiting, gastrointestinal pain, 
diarrhoea or constipation, and mucosal damage ranging from petechial haemorrhages to 
severe ulceration and even perforation (Carson and Strom, 1988). Because o f the blood
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and plasma protein loss, gastric and intestinal ulcerations are often accompanied by 
secondary anaemia and hypoproteinaemia (Jenkins, 1987). The primary cause o f the 
gastrointestinal side effects is the inhibition o f prostaglandin synthesis in the gastric 
mucosa. Mucosal prostaglandins normally inhibit gastric acid secretions and appear to 
have a "cytoprotective effect" by promoting gastric and intestinal mucus production and 
strengthening the mucosa against the back-diffiision o f acid from the lumen o f the stomach 
into the submucosal tissue, where it can cause damage (Ivey, 1986). Also, gastric 
prostaglandins are important in the maintenance o f gastric submucosal blood flow 
(Rainsford, 1975). NSAIDs are generally weak organic acids with pKa values o f  3-6 and 
so the drug remains largely unionised in the acid medium o f the stomach. Being lipid 
soluble in the stomach, NSAIDs are able to diffuse through the lipid bilayer o f  the gastric 
lining cells. Once in these cells where there is a relatively higher pH, the NSAID re-ionises 
and becomes trapped, resulting in prolonged and relatively high concentrations o f drug 
within the gastric lining cells. This causes cells to die with the development o f an ulcer 
(Ivey, 1986). The drug's anti-inflammatory effect itself then inhibits the inflammatory 
reaction and repair process around the dead cell and ulcer, thereby preventing the ulcer 
from healing. Gastrointestinal intolerance can occur whether the NSAID is given orally or 
systemically. However, the gastric effects are worse when the drug is administered orally 
rather than parenterally, as this results in higher local concentrations (Ivey, 1986).
b) Renal
Prostaglandins PGE2, and PGI2 are potent renal vasodilators in dogs (Fulgraff et al, 1974; 
Hill and Moncada, 1979). They are produced and metabolised locally by the kidney, where 
they contribute to the autoregulation o f renal blood flow, renin release, tubular ion 
transport, and water metabolism (Lifschitz, 1981; Schnermann and Briggs, 1981; Kokko, 
1981; Walker et al, 1981). In the normal animal renal prostaglandins do not appear to be 
important in the control o f resting renal blood flow or glomerular Alteration rate (Kore, 
1990). However, in adverse conditions where systemic vasoconstriction has been induced 
by mediators such as noradrenaline, alpha adrenergic stimulation and angiotensin n, renal 
prostaglandins act as vasodilators to maintain renal blood flow and urine output, thereby 
preserving renal perfusion and preventing the development o f acute renal failure (Rhymer, 
1985; Pirson and van Ypersele de Strihou, 1986; Patrono and Dunn, 1987; Boothe, 1989). 
In general, stimuli that produce renal vasoconstriction, renal ischaemia or both, produce 
an increase in the renal synthesis o f  PGE2, which is considered to be compensatory, in that 
these vasodilatory compounds attenuate the extent o f renal vasoconstriction (McGiff et al,
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1970). In these situations if the potentially vasodilating effects o f PGE2  and PGI2  are 
eliminated by the use o f NSAIDs, renal plasma flow and the glomerular Alteration rate 
decrease, resulting in prerenal azotemia and renal failure from unopposed renal 
vasoconstriction (Jenkins, 1987; Boynton, 1988; Aronoff^ 1992).
Prostaglandins in the kidney also play an important role in salt and water homeostasis. 
Prostaglandins are known to be natriuretic and NSAIDs, by interfering with this action, 
can cause sodium and water retention and oedema (Kimberley and Plotz, 1977; Kincaid- 
Smith, 1986).
With chronic use, and again in the presence of predisposing factors, NSAIDs have been 
incriminated in the development o f papillary or renal crest necrosis and chronic intestitial 
nephritis (Abraham and Keane, 1984). However the precise pathogenesis o f these lesions 
remains unclear. In humans, acute allergic interstitial nephritis has been reported as a 
direct effect o f NSAIDs (Abraham and Keane, 1984). It is an idiosyncratic reaction, where 
the patient develops acute renal failure with proteinuria. It can occur any time after 
initiation o f NSAID treatment, however it is usually seen 2 weeks to 18 months after 
initiation o f chronic NSAID therapy. Recovery is usual when NSAID therapy is 
terminated (Aronofl^ 1992) (Figure 3).
1.3.4. Pharmacokinetics of NSAIDs
Most NSAIDs, being relatively small weak acids, are readily absorbed from the proximal 
small intestine or stomach (Jenkins, 1987). However a number o f factors may influence 
this process (Davis, 1983), the most important being species, gastrointestinal motility, 
intragastric pH, presence o f food, pathological lesions, and concentration o f the drug 
(Jenkins, 1987). Peak concentrations are delayed and reduced when NSAIDs are 
administered with food but feeding generally has no effect on the bioavailability o f the 
drug (Lombardino, 1985). However, differences in drug disintegration and dissolution 
may lead to differences in bioavailability o f some drugs (Brater, 1988). Although the oral 
route o f administration is the most commonly used, a few NSAIDs are available as 
solutions for parental administration. However, with the exception o f fhinixin meglumine 
and carprofen, most o f these preparations are highly alkaline and are, therefore, irritant to 
the tissue when administered by intramuscular or subcutaneous injection (Jenkins, 1987). 
Because NSAIDs are largely ionised at physiological pH, they are essentially confined to 
plasma and extracellular fluid (Flower et al, 1986; Brater, 1988; Conlon, 1988). The
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Figure 3 : The effect of NSAlD-induced prostaglandin synthetase inhibition on renal physiology.
NSAID |
PROSTAGLANDIN
INHIBITION
CHLORIDE
ABSORPTION
RENAL 
BLOOD FLOW
GFR
SODIUM
RETENTION
OEDEMA
HYPERTENSION
BUN
CREATININE
ALDOSTERONE
RENIN
POTASSIUM
RETENTION
. 1-----
| HYPERKALAEMLA
GFR = Glomerular filteration rate
BUN = Blood urea nitrogen
NSAID = Non steroidal anti-inflammatory drug
23
volume o f distribution o f NSAIDs is small, often less than 10% o f body weight 
(Verbeeck, 1983). This is because a very large amount of drug is bound to albumin, leaving 
only a small portion unbound and pharmacologically active (Verbeeck, 1983; Murray and 
Brater, 1990). Despite that, their lipid solubility enhances penentration o f cell membranes 
(Boothe, 1989) and the extravasation o f plasma proteins through damaged capillaries into 
inflamed tissue further concentrates the amount o f NSAID at the target site. 
Consequently, because o f the acidic pH o f inflamed tissues the local therapeutic 
concentrations o f NSAIDs may be retained in the inflamed tissue after plasma 
concentrations have declined to subtherapeutic levels (Higgins, 1985; Lees et al, 1987). 
As a result o f this, NSAIDs have a duration o f analgesic activity far in excess o f that 
predicted by their relatively short half-lives and there is increasing evidence to suggest that 
such drugs can be given less frequently than would be predicted by their plasma 
concentrations, without compromising their effectiveness.
Metabolism o f NSAIDs is usually hepatic, mediated by the mixed function oxidase system 
(Davis, 1983; Dubinsky et al, 1987; Verbeeck, 1988). Enterohepatic circulation is 
common in dogs (Duggan et al, 1975; Risdall et al, 1978; McKellar 1989). Conjugates in 
the bile may be cleaved in the gut to generate the free acid which can then be reabsorbed 
in the lower intestine. This regeneration o f active drug may cause local mucosal irritation 
and damage, and it also prolongs the half-life o f the drug.
Excretion is mainly renal, usually by glomerular filtration and tubular secretion but some 
biliary elimination o f conjugates is possible (Jenkins, 1987). The rate o f renal excretion is 
frequently pH dependent (Flower et al, 1986) and the reabsorption from the renal tubules 
of acidic NSAIDs, which have a pKa o f between 3 and 7.5, is sensitive to alterations in 
urinary pH. Excretion is increased as the urine is alkalinised, a factor which is important in 
the treatment o f drug overdose.
There is species variation in both metabolism and excretion o f the different NSAIDs (Lees 
and Higgins, 1985). This variation in the elimination kinetics o f NSAIDs makes 
interspecies extrapolation extremely hazardous because cumulative tissue concentrations 
of NSAIDs may result in frank toxicity and are potentially fatal (Jenkins, 1987). The 
classic example o f this phenomenon is the plasma half-life o f aspirin in the horse, dog and 
cat, which is 1, 8 and 38 hours respectively. In addition, within the canine species, 
different breeds are said to demonstrate different rates o f drug clearance. Beagles are said
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to clear certain drugs more quickly than do mongrels (Runkel et al, 1972; Freh et al, 
1979; Freh and Rieh, 1981; Freh and Loscher, 1985).
NSAIDs are without exception characterised by a high degree o f binding to plasma 
proteins, some as high or higher than 99% e.g. meclofenamic acids (99.8%); flunixin and 
naproxen > 99% (Murray and Brater, 1990). Because o f the high protein binding o f  
NSAIDs, the pharmacokinetics o f these compounds and the availability o f free 
pharmacologically active drug can be altered by hypoproteinemia and the presence of  
other highly protein bound drugs.
1.4 FLUNIXIN MEGLUMINE
Flunixin meglumine (2{2-methyl-3 trifluromethylanilino}-nicotinic acid) is a nicotinic acid 
derivative with both analgesic and antipyretic activity (Sackman, 1991). It was approved 
for equine use alone in 1977 (Ciofalo, 1977), and was licensed for use in the dog in the 
U.K. in 1989. It is available both as an oral (granules and tablets) and a parental 
formulation (sub-cutaneous, intramuscular and intravenous routes). Figure 4 shows the 
chemical structure o f flunixin.
1.4.1 Mechanism of action of flunixin
Flunixin meglumine acts as a reversible inhibitor o f the enzyme cyclo-oxygenase (Semrad 
et al, 1985; Higgins et al, 1986; McKellar et al, 1989).
Figure 4- Chemical structure o f flunixin meglumine
C 00H
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1.4.2 Uses of flunixin
Flunixin is a potent analgesic especially in inflamed soft tissue, and is effective in 
controlling both somatic and visceral pain (Zederfeldt et al, 1977; Jenkins, 1987). It is 
indicated for the alleviation o f inflammation and pain in acute episodes o f musculoskeletal 
disorders (McKellar et al, 1991a). Dubinsky et al (1987), as well as Reid and Nolan 
(1991), found flunixin to be as effective as opioids in controlling post-operative pain. It 
can be used as the sole analgesic for moderate to severe pain or as an adjunct to opioids 
when pain is extremely severe and difficult to control. Flunixin can also be used as an 
adjunct in the therapy o f endotoxic or septic shock (McKellar et al, 1991a). It is useful in 
the treatment of inflammatory occular conditions, as it inhibits the prostaglandins which 
are thought to cause conjunctival hyperaemia and congestion o f the iris vasculature 
(McKellar et al, 1991a). It is generally thought to be more effective if  it can be given 
prophylactically in ocular cases, prior to surgery (Vestre and Krohne, 1988).
1.4.3 Pharmacokinetics of flunixin
The pharmacokinetics o f flunixin have been studied in conscious healthy dogs (Hardie et 
al, 1985; McKellar et al, 1989; McKellar, 1991b) and its average half-life after Lv. 
administration o f 1.1 mg/kg, was found to be approximately 3.5 hours. As flunixin 
penentrates acute inflammatory exudate readily and is cleared from it slowly, the actual 
elimination o f the drug from the site o f inflammation is considerably slower than the 
plasma elimination half-life, thereby providing analgesic and anti-inflammatory effects at 
the site o f injury well beyond the half-life o f the drug (Rubin and Papich, 1988). In horses, 
concentrations o f flunixin in exudate may be up to four times as high as concentrations in 
plasma after intravenous administration of 1.1 mg/kg, and significant eicosanoid inhibition 
remains at the site o f inflammation for up to 24 hours (Lee and Higgins, 1984; Higgins et 
al, 1986). It is likely that similar peripheral disposition o f flunixin will occur in the dog 
(McKellar et al, 1989; McKellar et al, 1991a). Hence, despite the relatively short plasma 
elimination half-life in the dog, the recommended interdosage interval o f 24 hours can be 
justified. This localisation o f the drug at the site o f injury may allow for a high level o f  
therapeutic effect while simultaneously avoiding undesirable side effects.
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1.4.4. Toxicity of flunixin
Flunixin is a potent analgesic but has a narrow therapeutic index in the dog (McKellar et 
al, 1989). A once daily regimen o f flunixin (1.1 mg/kg) has been recommended by 
McKellar et al (1989) as this allows the elimination o f most of the drug from plasma, 
provides a wash out period for circulating drug and thus minimises any risk o f systemic 
accumulation and toxicity (McKellar et al, 1989). It should however only be used for a 
maximum o f 3 days, with the course repeated after 4 days (i.e. 3 days on/4 days off 
schedule), since prolonged continuous therapy often results in gastrointestinal problems 
(Cosenza, 1984; Dow et al, 1990). It is for this reason that its use is limited in 
osteoarthritis to the control o f pain and inflammation only in acute exacerbations o f the 
clinical signs and not for long term control o f the condition.
1.5 ANAESTHESIA AND RENAL BLOOD FLOW
According to Schwenzer and Miller (1989), renal blood flow (RBF), in healthy animals far 
exceeds the kidney's metabolic demands, with each kidney receiving approximately 10 
percent o f the cardiac output, while they constitute only 0.4 percent o f the body weight 
(Rosen, 1972). Almost all o f the blood supplied to the kidney flows through the afferent 
arterioles o f the glomeruli (Rosen, 1972). The cortex receives three-quarters o f the total 
renal blood flow, while the juxtamedullary cortex and outer medulla receive one-fifth of  
the flow at a slower rate. The flow to the inner medulla is even slower, allowing the 
maintenance o f the high concentration o f solute observed in this region. Renal blood flow 
is regulated by both intrinsic and extrinsic factors. Local and humoral factors govern 
passive changes in the vascular resistance o f the afferent and efferent arterioles to maintain 
renal blood flow over a wide range o f mean arterial pressures (80-180 mm Hg). The 
ability o f  the kidney to autoregulate its blood flow and hence control its glomerular 
filtration rate over a wide range o f perfusion pressures has been described by numerous 
theories (Bevan et al, 1979), but is probably centred in the afferent arteriole (Schwenzer 
and Miller, 1989).
General anaesthesia produces haemodynamic changes that indirectly alter renal blood flow 
and function (Schwenzer and Miller, 1989). For many years it was thought that 
anaesthesia decreased renal blood flow due to lowered blood pressure and a compensatory 
renal vasoconstriction. However, Priano (1985) demonstrated that a moderate level of  
halothane does not significantly decrease renal blood flow in dogs but decreases renal
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vascular resistance in the face o f decreased blood pressure, thus maintaining renal blood 
flow, i.e., autoregulation is preserved (Schwenzer and Miller, 1989). Hunter et al (1981), 
recorded similar results. They stated that in dogs given Halothane at 1 MAC, renal 
autoregulation was preserved and renal blood flow and urine production well maintained, 
until a marked fall in cardiac output and mean arterial blood pressure occurs.
Antidiuretic hormone (ADH) is secreted by the hypothalamus to osmoregulate and 
conserve volume, by increasing the permeability of the collecting ducts and allowing 
reabsorption o f water (Schwenzer and Miller, 1989). It was originally thought that 
anaesthesia caused a direct release o f  ADH and decreased urine output (Papper et al, 
1957). However, Philbin and coworkers (Philbin and Coggins, 1978) demonstrated that 
light halothane anaesthesia did not measurably affect ADH levels in man. Surgical 
stimulation, however, produced marked increases in plasma ADH levels. Levels return to 
normal over 2-3 days after major surgery as long as there is haemodynamic stability 
(Moran et al, 1964).
The renin-angiotensin-aldosterone system is intimately involved in the regulation o f blood 
pressure and electrolyte balance, as well as in the regulation o f renal blood flow 
(Schwenzer and Miller, 1989). A reduction in blood volume or pressure, or 
vasoconstriction o f renal arteries as a result o f sympathetic stimulation accompanying 
surgery, decreases afferent arteriole pressure which leads to renin release from the kidney 
(Blaine and Davis, 1971). Renin converts angiotensinogen, to angiotensin I, which is then 
converted to angiotensin II by converting enzymes in the lungs and plasma. Angiotensin II 
is a potent renal vasoconstrictor decreasing renal blood flow (Bevan et al, 1973). It also 
stimulates the adrenal cortex to release aldosterone which increases tubular resorption o f  
sodium and excretion o f potassium, leading to expansion o f the extracellular fluid 
compartment and correction o f blood pressure. By causing a rise in blood pressure, 
aldosterone acts as a feedback mechanism to shut off further renin release (Schwenzer and 
Miller, 1989). There are conflicting reports on the effect o f anaesthesia and surgery on the 
renin-angiotensin system, Pettinger and colleagues (1975) demonstrated increased plasma 
renin activity in rats, using halothane while Robertson and Michelakis (1972), Bailey et al 
(1975) and Miller et al (1978) all showed no change in plasma renin activity in man and in 
rats using halothane anaesthesia. Most agree, however, that plasma renin activity rises 
significantly with surgical incision.
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Anaesthesia has been associated with increased aldosterone levels (Schwenzer and Miller, 
1989) which may indirectly be due to changes in arterial blood pressure and sympathetic 
stimulation via the renin-angiotensin system rather than changes in electrolyte balance. The 
mechanism o f this is not been clearly understood.
Vasodilating prostaglandins have been isolated from the renal medulla (Horton, 1972). 
The effect o f renal prostaglandins in regulating renal blood flow remains controversial. 
Arachidonic acid stimulates renin release in several animal models via its conversion to 
prostaglandins, specifically PGE2 and PGI2 and prostacyclins (Freeman et al, 1984). Oates 
et al (1979), through the use o f pharmacological inhibition o f prostaglandin synthesis with 
NSAIDs have provided evidence o f prostaglandins modulating role rather than a 
controlling role in renin-angiotensive system release. Angiotensin II also stimulates the 
secretion o f  prostaglandins. Prostaglandins, specifically PGE2 appear to oppose the 
vasoconstrictive effects o f angiotensin in acute renal failure (Schwenzer and Miller, 1989). 
By using NSAIDs which inhibit prostaglandin synthesis, angiotensin release is unopposed 
and can severely compromise renal blood flow (Stoff and Clive, 1983).
1.6 OBJECTIVE OF STUDY
NSAIDs are convenient and useful drugs to use as analgesics in dogs undergoing surgery. 
As flunixin was shown to be a potent analgesic, it was considered the NSAID o f choice, to 
treat post-operative pain in dogs. Experimental studies, have shown that acute pain may 
be eliminated or reduced if the excitability of the CNS is suppressed with opioids before it 
receives a nociceptive input (W oolf and Wall, 1986b; Dickenson and Sullivan, 1987). 
Similarly, anti-nociceptive procedures were found to be less effective when applied post­
injury (W oolf and Wall, 1986a and b; Dickenson and Sullivan, 1987; Coderre et al, 1990). 
Consequently, the o f timing o f analgesia has been considered important in the treatment o f  
post-operative pain (W oolf and Wall, 1986a and b; Wall, 1988; Wool£ 1989). In order, to 
obtain the maximum benefit from its anti-inflammatory action, it appeared reasonable to 
administer flunixin before tissue trauma occured, i.e. before surgery. Recently however, 
flunixin given peri-operatively has been implicated in renal toxicity in dogs following 
surgery (McNeil, 1992; Elwood, 1992). Both reported cases o f fatal renal toxicity in dogs 
given flunixin in the intra-operative period along with other drugs, and they suggested that 
flunixin administration was best avoided intraoperatively. Consequently, the manufacturers 
of flunixin, have since recommended that flunixin administration should be delayed until 
the end o f surgery.
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Pharmacokinetic studies on flunixin have been performed in conscious dogs (Hardie, 
1985; McKellar et al, 1989; McKellar et al, 1991b), but no kinetic studies have been 
carried out on dogs under, or just recovering from anaesthesia, which is the period when 
the drug is most frequently used in clinical practice. All general anaesthetics alter renal 
haemodynamics (Deutsch and colleagues, 1969) and clinically useful concentrations o f  
halothane cause a reduction in the glomerular filtration rate which may theoretically 
enhance the toxicity o f NSAIDs. General anaesthetics also cause a decrease in hepatic 
blood flow (Ahlgren et al, 1967) which may affect metabolism and pharmacokinetics o f  
drugs given to the anaesthetised animal. This study was undertaken to determine the 
pharmacokinetics o f flunixin in the anaesthetised dog, injected prior to the start o f surgery, 
as well as in the immediate post-operative period, and to determine whether there was any 
significant difference in the pharmacokinetic parameters obtained between these 2 groups. 
Alterations in kinetic parameters contributing to higher plasma levels o f the drug and 
prolongation of its action might be expected to contribute to drug toxicity such as that 
described by McNeil (1992) and Elwood (1992).
A further objective was to monitor renal function in a group o f dogs which had 
anaesthesia and surgery but no NSAJD and to compare this with the dogs given flunixin 
pre and post surgery. BUN, serum creatinine and phosphate were used as indices o f renal 
function, as most patients suffering from NSAID-induced renal damage, experience a 
sudden decrease in their glomerular filtration rate (Aronoff 1992), and demonstrate 
increases in BUN and serum creatinine levels within the first 24 hours o f  treatment with 
the NSAJD (Aronofl^ 1992). In the light o f these findings it was hoped to elucidate 
whether giving flunixin post surgery is indeed safer than the pre-operative use o f the drug.
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2. MATERIALS & METHODS
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2.1 ANIMAL DETAILS
Thirty mixed breed dogs undergoing anaesthesia and surgery were included in this study. 
The animals were between 7 months and 7 years o f  age and they weighed between 17 and 
44 kg. Details o f individual animals and surgical procedures are shown in Table 1 and 
Table 2. All dogs were free from signs o f cardiovascular and respiratory disease and had 
not received any non-steroidal anti-inflammatory drugs (NSAID) or corticosteriod 
medication for at least ten days prior to anaesthesia.
2.2 DRUG AND DOSING
A commercially available formulation o f flunixin meglumine injection, 50 mg/ml, was used 
in this study (Finadyne, Schering-Plough Animal Health, Suffolk, U.K.).
The manufacturer's recommended dose o f flunixin meglumine, 1.1 mg/kg was 
administered intravenously (i.v.) to each dog involved in the study.
2.3 TRIAL DESIGN
The dogs were allocated randomly into 3 groups o f 10 dogs each. Group A (n=10) 
received flunixin meglumine, 1.1 mg/kg, i.v. during anaesthesia, prior to the start of 
surgery, Group B (n=10) received flunixin meglumine, 1.1 mg/kg, i.v., immediately after 
surgery and anaesthesia had been terminated and Group C (n=10) received no flunixin.
2.3.1 Anaesthetic regime for dogs in the study
All dogs in the trial were examined clinically and weighed the day prior to anaesthesia and 
surgery. They were starved overnight and water was withheld on the morning of 
anaesthesia and surgery. On the day o f anaesthesia, the dogs were re-examined. In dogs 
trial No: 4, 6, 7, 8, 9 and 10 (group A), and all dogs in group B (Trial No: 11-20) indirect 
blood pressure readings were taken using the DINAMAP (Critikon, Model 
number: 1846sx; Tampa FL 33630).
All animals were premedicated with an intramuscular injection o f acepromazine maleate 
(ACP Injection; C-Vet limited; 2 mg/ml) at a dose rate o f 0.05 mg/kg for medium sized
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TABLE 1
Details o f individual animals used in the study together with the surgical procedure 
undertaken. Dogs numbered 1-10 received flunixin meglumine, 1.1 mg/kg, i.v. during 
anaesthesia before the start o f surgery, while dogs numbered 11-20 received flunixin 
meglumine, 1.1 mg/kg, i.v. immediately after surgery and anaesthesia had terminated.
TRIAL
NO
BREED SEX AGE WT
(Kg)
SURGICAL
PROCEDURE
1 Greyhound F 4 years 22.5 Implant removal
2 Rottweiler M 10 months 38.5 OCD flap removal
3 German Shepherd 
Cross
F 2.5 years 37 Flexor tendon repair
4 Newfoundland F 3.8 years 44 Biopsy mass
5 Labrador/ Retriever 
Cross
M 7 months 33 Removal o f ununited 
coronoid process
6 German Shepherd F 5 years 39 Anal furunculosis
7 Dalmatian M 8 months 29.8 Arthrotomy-shoulder
8 Cross-Breed M 4.5 years 28 Castration
9 German Shepherd 
Cross
M(N) 5.5 years 36 Explore wound in neck
10 Grey Hound F 4.5 years 28.75 Elective dental
11 Irish Spinone F 9 months 31 OCD flap removal
12 Labrador Cross F(N) 4.5 years 44 Carpal arthrodesis
13 Rottweiler F(N) 1.5 years 17.8 Cruciate repair
14 Bernese Mountain 
Dog
M 1 year 44.5 OCD flap removal
15 Grey Hound F 7 years 26.25 Elective dental
16 Lurcher Cross M 4 years 26 Internal fixator 
application
17 Border Collie M 4 years 27 Anal furunculosis
18 Retriever F(N) 2.1 years 35 Cruciate repair
19 Border Collie M 3.5 years 22.75 Enucleation
20 German Shepherd F 5.5 years 36 Ovario-hysterectomy
ABBREVIATIONS USED
No - Number WT - Weight Kg - Kilogramme
F - Female F(N) - Neutered female M(N) - Neutered male
M - Male OCD - Osteochondrosis
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dogs or 0.03 mg/kg for large breed dogs. The dogs were left undisturbed for 
approximately 45-60 minutes while sedation took effect.
A sterile indwelling over-the-top type teflon intravenous catheter (Intraflon 2; Vygon 
Laboratoires Pharmaceutiques, France) with a 3-way tap attached was placed in the 
cephalic vein. Anaesthesia was induced using 2.5% thiopentone sodium (Intraval sodium; 
Rhone Merieux limited) given intravenously through the preplaced catheter at a dose of 
approximately 10 mg/kg. Endotracheal intubation was performed immediately after 
induction and anaesthesia was maintained with halothane (Fluothane; ICI 
Pharmaceuticals,U.K.) in a 2:1 nitrous oxide/oxygen mixture delivered via a non­
rebreathing Magill circuit with a fresh gas flow o f 200 ml/kg/minute. Immediately after 
anaesthesia was induced, Hartmann's solution (Aqupharm; Animal Care Limited) was 
administered via the catheter already present in the cephalic vein, at a rate o f 5 ml/kg/hr.
Monitoring during anaesthesia
Pulse and respiratory rates were monitored throughout anaesthesia and recorded at 5 
minute intervals. Blood pressure was measured using the DINAMAP which measures 
blood pressure indirectly using the principle o f doppler shift sphygmomanometry. In order 
to ensure that indirect blood pressure readings were relatively accurate, care was taken to 
ensure firstly, that the cuff fitted snugly around the chosen appendage. This was achieved 
by using a cuff the width o f which was 0.4 x the circumference o f the limb in centimeters 
(Hassler et al, 1977; Geddes et al, 1980), at the site of application and secondly, that the 
cuff lay at the level o f the heart whilst the blood pressure readings were being taken. 
Recordings were taken every 5 minutes from induction o f anaesthesia until the dog 
regained sternal recumbency. End tidal carbon dioxide (ETCO2 ) levels were measured 
during surgery in dogs trial number 1, 2, 3, 8, 9, 10, 11, 12, 14, 16, 17, 18, 19 and 20, 
using an infrared carbon dioxide analyser (Normocap CO2 & O2 monitor; Datex 
Instrumentarium, Finland) and were recorded from the beginning o f surgery every 5 
minutes until the trachea was extubated.
Ten minutes before the end o f anaesthesia, 100% oxygen was administered as the sole 
carrier gas for the remainder o f  the procedure. As the halothane was switched off 
administration o f Hartmann's intravenous fluid was terminated. The dogs were placed in 
recovery kennels after extubation until they regained full consciousness.
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In all 20 dogs undergoing the trial, blood was collected prior to the induction o f  
anaesthesia and flunixin administration, and biochemical analysis was performed on the 
samples. The biochemical parameters examined were urea, creatinine and phosphate, 
together with total protein, albumin, globulin, sodium, potassium and chloride, if  the 
samples were large enough to permit these further tests. Blood samples at 12 and 30 hours 
after flunixin administration, were also sent for biochemical analysis, to determine whether 
there was a significant rise in the above mentioned parameters as a result o f flunixin 
administration. In dog no 8, a further blood sample was taken for biochemical analysis, 60 
days after flunixin administration, while in dogs no 10 and 15, 15 day and 60 day samples 
were taken and in dog no 10, a 150 day sample was taken for biochemical analysis.
To determine whether anaesthesia and surgery without flunixin administration altered 
biochemical parameters, a control group o f 10 dogs, Group C (Trial Nos: Cl - CIO) were 
used. These dogs underwent exactly the same anaesthetic regime as the trial dogs in 
Group A and Group B, the only difference being that they received papavertum 
(Omnopon 10 paediateric; Roche), 0.2-0.4 mg/kg i.m , as the analgesic in the intra- and 
post-operative period. Details o f the individual animals in the control group, and the 
surgical procedure undertaken by them are given in Table 2.
2.3.2 Administration of Flunixin meglumine
Group A
After induction o f anaesthesia and before the start o f surgery, once the dog was 
considered to be in a stable plane of anaesthesia, flunixin meglumine, 1.1 mg/kg, was 
administered through the indwelling cephalic catheter as a slow intravenous injection over 
a period of 30 seconds. Blood samples were taken from a catheter placed in the lateral 
saphenous vein.
Group B
On completion o f surgery and immediately on termination o f  anaesthesia, flunixin 
meglumine, 1.1 mg/kg, was administered through the indwelling cephalic catheter as a 
slow intravenous injection over a period of 30 seconds. Blood samples were taken from 
the saphenous catheter.
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2.3.3 Blood sampling details
Blood samples (2-3 ml) were withdrawn from the lateral saphenous vein catheter into 
heparinised plain sterile plastic 10 ml tubes (Monovette® blood collection system, 
SARSTEDT, Germany) immediately before intravenous administration o f flunixin 
meglumine (pre-sample); then 2, 5, 10, 15, 20, 30, and 45 minutes and 1, 1.5, 2, 4, 6, 8, 
10, 12, 20, 24 and 30 hours after administration o f flunixin. After collection, the blood 
samples were gently mixed and placed immediately in an ice box. The patency o f the 
saphenous vein catheter was maintained during the 30 hour bleeding period by flushing it 
with diluted heparin saline solution (10 units o f  heparin/ ml o f saline) after every blood 
sample was taken. Care was taken to discard the heparin solution before each blood 
sampling time.
2.4 STORAGE OF SAMPLES
The heparinised blood samples from each dog were centrifuged at 1400 g* force for 15 
minutes in a refrigerated centrifuge at 4°C within 4 hours o f collecting the blood. The 
plasma was then decanted into 5 ml plastic bottles and was frozen at -20°C until analysed, 
within 2 months o f collection. Previous studies carried out in the Department o f  
Veterinary Pharmacology, Glasgow University, indicated that there was no loss o f drug 
when stored over this time period.
2.5 ANALYSIS OF SAMPLES FOR FLUNIXIN
The concentration o f flunixin meglumine in plasma was analysed by High Performance 
Liquid Chromatography (HPLC).
2.5.1 Extraction and reconstitution of drug
Each plasma sample was defrosted at room temperature, and 0.25 ml o f plasma was 
placed in a 10 ml stoppered glass test-tube. Seventy-five microlitres o f citrate/phosphate 
buffer (PH 3) [20.5% M/5 Na2HPC>4 : 79.5% M/10 Citric acid] was added to the 
sample in order to acidify it. Six ml o f chloroform (HPLC Grade - Rathbum Chemicals 
limited) was then added to the buffered plasma and a clean glass stopper placed tightly on 
the test-tube. The mixture was shaken gently for 10 minutes on a rotary mixer and then
36
centrifuged at 2800 g* force for 15 minutes in a refrigerated centrifuge at 4°C. Following 
centrifugation, 4 ml o f the lower chloroform layer was recovered and transferred into 
clean 10 ml thin walled glass centrifuge tube. The aliquot was then evaporated to dryness 
on a Dri-block (Model DB.3 Techne, Cambridge ltd) at 50°C under a gentle stream of air. 
Following evaporation to dryness, the residue was reconstituted in 150 pi o f methanol. 
(HPLC Grade - Rathbum Chemicals limited). This sample was vortexed for 5 seconds, 
placed in a sonic bath for 2 minutes and revortexed for 5 seconds to ensure reconstitution 
o f the drug in methanol. Subsequently, 125 pi o f this mixture was transferred into a clean 
glass vial which was capped with cling film and placed in an autoinjector.
2.5.2 Injection of Drug
All samples were analysed on an HPLC system (Spectra Physics Isochrome LS Pump, 
Model 231) which was equipped with an autoinjector (Gilson Auto-sampling Injector, 
Model 231-401) and a variable wavelength detector (Spectra 100 UV-Vis Detector, 
Model No A009-307A 4/89). The output from the detector was connected to a chart 
recorder (RIKADENKI Kogyo Co ltd, Model No R-01).
The samples were chromatographed on a C-8, 5 p BDS Hypersil column with guard, 
using 70:30 methanol: water mobile phase containing 400pl/100ml perchloric acid [1/55 
dilution o f 70% H3P04]. Permaganate distilled water was used instead o f  undistilled water 
as impurities capable o f degrading the HPLC column are present in undistilled water. The 
mobile phase was pumped through the column at a flow rate o f 1 ml/minute. Complete 
chromatographic parameters are listed in Table 3
2.5.3 Drug recovery and calculations
In order to calculate the concentration o f flunixin in the plasma sample, a known standard 
concentration o f flunixin (External standards) was injected after every plasma sample. The 
peak height o f flunixin in the plasma sample was then compared to the peak height o f the 
external standard. Allowances were made for the physical recovery o f the drug from 
plasma, as described below.
* g = gravitational
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TABLE 2: Details o f individual animals used in the control study together with the 
surgical procedure undertaken. Dogs numbered C1-C10 received flunixin meglumine, 1.1 
mg/kg, i.v. during anaesthesia before the start o f surgery.
TRIAL
NO
BREED SEX AGE WT
(Kg)
SURGICAL
PROCEDURE
Cl Newfoundland F(N) 4 years 40 Cruciate repair
C2 Border Terrier F 7.5 years 6.5 Cataract removal
C3 Labrador M 7 months 29.5 OCD flap
C4 Cross M 6 years 15.5 Trephination o f eye
C5 Cross M 5 years 15.5 Examine eye
C6 Bouvier F(N) 2.5 years 32 Repair metacarpal 
fracture
C7 Rottweiler M 2 years 53 Cruciate repair
C8 Airedale F(N) 7.5 years 31 Total ear canal 
ablation
C9 Rottweiler F 4 years 37 Cruciate repair
CIO Staffordshire Terrier M 2.5 years 17 Cruciate repair
ABBREVIATIONS USED
No - Number WT - Weight Kg - Kilogramme M - Male
F - Female F(N) - Neutered female OCD - Osteochondrosis
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TABLE 3 - Chromatographic settings used for the determination o f flunixin in dog plasma
SYSTEM CONTROLLER
Flow Rate: 1 ml/minute (PSI = 1500 -1800)
Loop Size: 20 pi
AUTOINJECTOR
Injection volume: 15 pi
Analysis Time: 6.5 minutes
DETECTOR
Wave length: 287 nm
Absorbance variable depending on the drug concentration ( 0.001 - 0.05 )
CHART RECORDER
Chart Speed: 30 cm/hr
Recorder setting: 10 mV
EXTERNAL STANDARDS
A stock solution o f flunixin meglumine, 1 mg/ml in methanol was prepared using flunixin 
meglumine powder (QC Number: 091889, CAS Number: 42461-84-7, Expiry date: 1994). 
From this stock solution the following flunixin standards were prepared, 500, 200, 100, 
40, 20, 10, 5, 2, 1 and 0.5 pg/ml. The standards were stored under refrigeration at 4°C 
when not in use. Fresh standards were made every 3 months.For each batch o f extracts 
that were performed, spiked plasma samples with known concentrations o f flunixin (0.25, 
1, 2, 5, 10 and 25 pg/ml) were extracted simultaneously, so as to determine the mean 
recovery o f flunixin in every batch o f  extractions that were carried out. Allowances were 
made for the physical recovery o f the drug from plasma. The expected proportion of 
flunixin extracted from chloroform was 66 %, as only 4 ml o f chloroform from the original 
6 ml added was recovered.
SPIKED SAMPLES
Spiked plasma samples were prepared by adding 12.5 pi o f known concentrations of 
flunixin meglumine (external standards), to 0.25 ml o f blank canine plasma. The following 
spiked plasma samples were made:
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0.25 ;ig/m1 flunixin- Add 12.5 |il o f 5 (ig/ml flunixin (ext std)46 to 0.25 ml canine plasma
1 (ig/ml flunixin  Add 12.5 \il o f 20 ng/ml flunixin (ext std) to 0.25 ml canine plasma
2 pg/ml flunixin  Add 12.5 p.1 o f  40 (ig/ml flunixin (ext std) to 0.25 ml canine plasma
5 f^g/ml flunixin  Add 12.5 fil o f 100 fig/ml flunixin (ext std) to 0.25 ml canine plasma
10 fig/ml flunixin— Add 12.5 pi o f 200 pg/ml flunixin (ext std) to 0.25 ml canine plasma
25 pg/ml flunixin— Add 12.5 pi o f 500 pg/ml flunixin (ext std) to 0.25 ml canine plasma
The concentration o f flunixin in spiked samples was determined by comparing the peak 
height o f the spiked sample with the peak height o f flunixin meglumine in external 
standards and adjusting the ratio for the expected 66.66% recovery. This allowed the 
mean recovery o f flunixin for a specific extraction to be calculated.
The formula below was used to calculate the concentration o f flunixin recovered in the 
spikes after extraction.
Concentration of flunixin recovered% RECOVERY = ------------------------------------------
Actual concentration of flunixin
n/ Spike peak ht.* _ . Analysis vol. 100 1% RECOVERY = —--- — x Std conc. x---------- -------------x --------x ---------------x 100
Std peak ht.* Plasma sample vol. 66.66 Spike conc.
( * = Chromatogram peak height and Std = Standard )
Once the mean recovery o f flunixin was determined for the particular extraction, the 
plasma concentration o f flunixin in the test samples was calculated in a similar manner. A 
conversion factor ( the reciprocal o f the recovery determined from the analysis o f the 
spikes ) was used to adjust the calculated concentration in the extracted sample to derive 
the actual plasma drug concentration.
 Sample peak ht.* „ , Analysis vol. 100 1FLUNIXIN RECOVERY = ------—---------- x Std conc. x---------  x ------- x -----------------------
Std peak ht.* Plasma sample vol. 66.66 % Spike recovery
46ext std = external standard
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2.5.4 Pharmacokinetic calculations
The plasma concentration data for flunixin in each dog was calculated by analysing the 
changes in the plasma drug concentration versus time, following a single intravenous bolus 
administration o f the drug. All the pharmacokinetic analyses o f concentration versus time 
data for each animal were performed using a non linear regression Fortran IV curve 
stripping pharmacokinetic computer programme, CSTRIP, (Sedman and Wagner, 1976). 
This programme generates up to 3 y-axis intercepts (B, A and P) and exponents ( P, a  
and n  ) (last to first) for the equation best describing the data, and a linear correlation 
coefficient. The number o f exponents best describing each data set was confirmed using 
Akaike's information criterion (Yamaoka et al, 1978 ).
The computed pharmacokinetic determinants obtained in CSTRIP were calculated using 
standard models and equations describing bi and tri-exponential decays. (Sedman and 
Wagner, 1976; Baggot, 1977)
The mathematical expression which best describes the plasma drug concentration-time 
profile for a bi-exponential decline following i.v. administration o f a single dose o f drug is
Cp = Ae"a  1 + Be'0 1
Where Cp is the concentration o f drug in plasm at at time t 
A and B are "intercept'’ terms with dimensions o f concentration (pg/ml) 
a  and (3 are the distribution and elimination rate constants respectively and are expressed 
in units o f reciprocal time (hr-1) 
e represents the base o f the natural logarithm.
The mathematical expression which best describes the plasma drug concentration-time 
profile for a tri-exponential decline following i.v. administration o f a single dose o f drug is
Q>= P ^ I, +  A ea t  + Be'Jt 
Where P, A and B are "intercept" terms with dimensions o f concentration (pg/ml)
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7i, a  are the distribution rate constants and (3 is the elimination rate constant. The rate 
constants are expressed in units o f reciprocal time (hr'1)
The elimination half life o f a drug, tl/2 P, is defined as the time required for the body to 
eliminate one-half o f the particular drug.
0.693 
t l / 2 ( P ) = — —
Vc (ml/kg) is the apparent volume o f the central compartment calculated from Dose/CpO.
Vdss (ml/kg) is the apparent volume o f the distribution at steady state concentration 
calculated from Dose (iv.).AUMC/AUC2.
CL|j (ml/kg.hr) is the body clearance o f a drug. It represents the sum o f all clearance 
processes in the body and is calculated from Dose/AUC.
kel (hr'1) is the first-order elimination rate constant for the disappearance o f a drug from 
the apparent central compartment. It is calculated from the ratio o f body clearance to the 
apparent volume o f the central compartment.
Non compartmental analysis o f the plasma flunixin concentration data was also carried out 
and mean residence time (MRT) calculated. MRT (hr) is a quantitative estimate o f the 
persistence o f a drug in the body, or the time for 63.2% o f a drug to be eliminated. It is 
calculated from AUMC0bs/AUC0bs, where AUMC0bs (}ig.hr2/ml) is the total area under 
the drug concentration time versus time or first moment curve, from time 0 to time 
infinity, after administration o f a single dose. It is calculated using the trapezoid rule and 
from A /a2+ B/p2+ P/712 (cal), and AUCobs (fig.hr/ml) is the total area under the drug 
concentration versus time or zero moment curve, from time 0 to time infinity, after 
administration o f a single dose. It is calculated using the trapezoid rule (obs) and from 
A/oc+ B/p+ P/71 (cal). The observed area under the first moment curve value (AUMCob) 
and the the observed area under the curve value (AUMC0bs) were obtained from the C- 
STRIP FORTRAN IV compartmental computer programme.
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2.5.5 Statistical analysis
Results are expressed as means + standard error o f the mean (SEM).
Comparison between weights, ages, anaesthetic and surgical times, in dogs in group A and 
group B,were made using an unpaired't' test, as all these sets o f results were found to be 
normally distributed, when normality plots were performed using MINITAB statistical 
computer package.
The difference in biochemical blood values, namely urea, creatinine, phoshate, total 
protein, albumin, globulin, sodium, potassium, chloride, and potassium from 0 hours to 12 
hours, between the dogs in the control group C (Trial No C1-C10), were compared using 
a 'two sample t test', with the difference in biochemical values from 0 hours to 12 hours, in 
dogs in group A and group B. This was followed by determining whether there was any 
significant differences in the kidney biochemical blood values, in the same time period (0 
hours to 12 hours) between dogs in group A (flunixin given prior to surgery) versus dogs 
in group B (flunixin given at the end of surgery), again using a 'two sample t test'. 
Similarly, comparisons between the differences in the biochemical blood parameters from 
12 hours to 30 hours, between dogs in the control group C (Trial No C1-C10) versus 
dogs in group A and group B (Trial No 1-10) were made using the same test. This was 
followed by comparing the differences in biochemical parameters from 12 hours to 30 
hours between dogs in group A versus group B.
The precision o f the HPLC extraction procedure, in a given assay was assessed by 
determining the coefficient o f variation, in replicated plasma samples, to which a known 
concentration o f the drug flunixin was added (spiked samples) and the samples analysed in 
a single assay. This was known as intra-assay coefficient o f variation or 'within day* 
variation, o f the flunixin HPLC analysis procedure. Refer to appendix C, table Cl. The 
degree o f variation between the 20 assays (dogs trial numbers 1-20), performed on 
different days, the inter-assay coefficient of variation or 'between days' variation, is shown 
in appendix C, table C2.
Comparisons between pharmacokinetic parameters o f dogs in group A versus dogs in 
group B were made using the Mann-Whitney U test, as these results were found not to be 
normally distributed when normality plots were performed using Minitab statistical 
software (version 7.2).
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3. RESULTS
44
3.1 ANAESTHETIC DETAILS
Demographic details o f the animals used in the study are given in table 4. All dogs were 
clinically normal prior to the start o f  the trial.
The mean age o f dogs in group A was 3.19 + 0.63 years (range, 7 months - 5.5 years), 
while in group B it was 3.38 + 1.37 years (range, 9 months - 7 years). Dogs in group A 
weighed 33.66 + 2.14 kg (range, 22.5 - 44 kg) and those in group B were 31.03 + 2.94 kg 
(range, 17.8 - 44.5 kg). There were no significant differences in the ages or weights o f the 
dogs in the 2 groups.
Details o f the duration o f anaesthesia and surgery together with the surgical procedure 
undertaken in each dog are documented in table 5. Details o f the time at which the 
analgesic flunixin was administered relative to the start or end o f anaesthesia are shown in 
table 6 (Group A) and table 7 (Group B). The mean anaesthetic time for dogs in group A 
was 109 ± 1 8  minutes, and in group B, 134 + 19 minutes. The samples were normally 
distributed and there was no significant difference in the anaesthetic times between the 2 
groups. The mean surgical time for dogs in group A was 50 + 9 minutes, which was 
significantly less than for dogs in group B, 84 + 13 minutes (P < 0.05). In group A, 
flunixin was administered approximately 12 + 2 minutes after induction o f anaesthesia and 
45 + 10 minutes prior to the start o f surgery (table 6). In Group B, flunixin was 
administered approximately 6 + 1  minutes after the termination o f surgery and 4 + 1  
minutes after the termination o f anaesthesia (table 7).
3.1.1 Physiological param eters
All animals in the trial remained stable throughout anaesthesia and recovery from 
anaesthesia was uneventful in all cases. Arterial blood pressure, pulse, respiration and 
ETCO2  readings for individual dogs are presented in Appendix A  (Table A1-A8). 
Graphical representation o f individual dogs arterial blood pressure, pulse, respiration and 
ETCO2  readings can also be found in Appendix A (Fig A1-A14).
A graph o f the means ± SEM47 o f the mean arterial blood pressure, pulse, and respiratory 
readings was also plotted for dogs in group A and group B, versus time (Fig 5-7).
47SEM = Standard error of means
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TABLE 4 : DETAILS OF ANIMALS USED IN THE TRIAL
Dogs 1-10 (group A) received flunixin meglumine, 1.1 mg/kg, i.v, during anaesthesia 
before the start o f surgery, while dogs 11-20 (group B) received flunixin meglumine, 1.1 
mg/kg, iv, at the termination o f anaesthesia. Anaesthesia was maintained in all cases with 
halothane in a 2:1 nitrous/oxygen mixture delivered via a non-rebreathing magill circuit, 
with a fresh gas flow o f 200 ml/kg/minute.
TRIAL NO BREED SEX AGE WT (Kg)
1 Greyhound F 4 years 22.5
2 Rottweiler M 10 months 38.5
3 German Shepherd Cross F 2.5 years 37
4 Newfoundland F 3.8 years 44
5 Labrador/ Retriever Cross M 7 months 33
6 German Shepherd F 5 years 39
7 Dalmatian M 8 months 29.8
8 Cross-Breed M 4.5 years 28
9 German Shepherd Cross M(N) 5.5 years 36
10 Greyhound F 4.5 years 28.75
11 Irish Spinone F 9 months 31
12 Labrador Cross F(N) 4.5 years 44
13 Rottweiler F(N) 1.5 years 17.8
14 Bernese Mountain Dog M 1 year 44.5
15 Greyhound F 7 years 26.25
16 Lurcher Cross M 4 years 26
17 Border Collie M 4 years 27
18 Retriever F(N) 2.1 years 35
19 Border Collie M 3.5 years 22.75
20 German Shepherd F 5.5 years 36
ABBREVIATIONS
M = Male F = Female M (N) = Neutered male F (N) = Neutered female
WT = weight Kg = Kilogramme
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Table 5 : Details o f anaesthetic time, surgical time and surgical procedure undertaken in 
dogs 1-20, where dogs 1-10 (group A), received flunixin, 1.1 mg/kg, i.v., preoperatively, 
and dogs 11-20 (group B) received flunixin, 1.1 mg/kg, i.v., post-operatively.
TRIAL
NO
ANAESTHETIC
TIME
SURGICAL TIME SURGICAL PROCEDURE
1 50 minutes 20 minutes Implant removal
2 2 hours 28 minutes 50 minutes Osteochondrosis flap removal
3 2 hours 41 minutes 1 hour 26 minutes Flexor tendon repair
4 1 hour 14 minutes 11 minutes Biopsy mass
5 2 hours 45 minutes 1 hour 12 minutes Removal o f ununited coronoid process
6 1 hour 40 minutes Anal furunculosis
7 3 hours 5 minutes 1 hour 40 minutes Arthrotomy- shoulder
8 1 hour 25 minutes 45 minutes Castration
9 1 hour 57 minutes 33 minutes Explore wound in neck
10 45 minutes 38 minutes Elective dental
11 2 hours 45 minutes 1 hour 25 minutes Osteochondrosis flap removal
12 3 hours 33 minutes 2 hours 13 minutes Carpal arthrodesis
13 2 hours 33 minutes 1 hour 30 minutes Cranial cruciate repair
14 3 hours 10 minutes 2 hours 10 minutes Osteochondrosis flap removal
15 22 minutes 18 minutes Elective dental
16 2 hours 11 minutes 1 hour 10 minutes Internal fixator application
17 1 hour 15 minutes 50 minutes Anal furunculosis
18 1 hour 58 minutes 58 minutes Cranial cruciate repair
19 1 hour 40 minutes 1 hour 10 minutes Enucleation
20 2 hours 51 minutes 2 hours 18 minutes Ovario-hysterectomy
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Table 6: Details o f flunixin meglumine administration in dogs in group A (Trial No: 1-10) 
from the start o f anaesthesia and prior to the start o f surgery.
Trial
No
Time o f administration o f flunixin 
after inducing anaesthesia
Time of administration o f flunixin 
prior to the start o f surgery
1 10 minutes 15 minutes
2 12 minutes 1 hour 26 minutes
3 18 minutes 53 minutes
4 5 minutes 54 minutes
5 21 minutes 1 hour 12 minutes
6 10 minutes 10 minutes
7 18 minutes 1 hour 7 minutes
8 12 minutes 18 minutes
9 10 minutes 1 hour 12 minutes
10 8 minutes 4 minutes
Table 7: Details o f flunixin meglumine administration in dogs in group B (Trial No: 11-20) 
from the termination o f surgery and anaesthesia.
Trial
No
Time o f administration o f flunixin 
after termination o f anaesthesia
Time o f administration o f flunixin 
after termination o f surgery
11 4 minutes 4 minutes
12 5 minutes 5 minutes
13 8 minutes 11 minutes
14 5 minutes 10 minutes
15 5 minutes 7 minutes
16 3 minutes 10 minutes
17 0 minutes 0 minutes
18 1 minutes 1 minutes
19 3 minutes 3 minutes
20 2 minutes 2 minutes
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Because o f the large variation in the anaesthetic times o f the individual dogs in the trial, 
only mean values up to 1 hour 45 minutes into anaesthesia were plotted. As is evident 
from the graphs, mean blood pressure, pulse, and respiration o f dogs in group A and B 
were very similar. Mean ETCO2  readings were not plotted as there were too few readings 
to be meaningfiil. Because o f the variations in the duration o f the anaesthetic times 
between the individual dogs in both group A and group B, and because o f some missing 
readings due to lack o f availability o f  Dinamap and ETCO2  monitors, it was not possible 
to carry out a statistical analysis o f these results. However, it was possible to plot the 
individual blood pressure, pulse, respiration and ETCO2  readings o f each dog in the trial, 
and by observing the graph shape determine whether there was any distinct trend in the 
above readings between groups A and B. As is clearly evident from these graphs 
(appendix A, figures A1-A14), no trend was obvious in any o f the clinical parameters 
analysed. Five dogs in group A (No's: 1, 5, 6, 7 and 10) and four dogs in group B (No's: 
12, 14, 16 and 20) became hypotensive during anaesthesia i.e. their mean arterial blood 
pressure readings fell below 60 mm Hg. With the exception o f dog 12 which remained 
hypotensive for 1 hour 10 minutes, these periods o f hypotension were short lived and did 
not persist beyond 15 minutes at a time. In dog 12, blood pressure remained stable 
between 55-59 mm Hg, but clinical indicators o f adequate perfusion such as pulse volume 
and mucus membrane colour remained good
Individual pulse readings were unremarkable in most dogs on trial, ranging between 75 to 
120 beats/minute, except for Dogs 1, 16 and 20. Dog 1 suddenly became tachycardic on 
recovery from anaesthesia. Dog 16 was tachycardic throughout, but had a fast heart rate 
prior to the start o f anaesthesia, while Dog 20 gradually became tachycardic during 
surgery.
Individual respiratory readings for dogs in group A and group B were unremarkable, with 
respirations ranging from 6-40 breaths/minute, except in dog 19, where it increased to 80 
breaths/minute and dog 20, where it increased to 50 breaths/minutes immediately before 
anaesthesia was terminated.
ETCO2  readings were normal throughout anaesthesia in all dogs examined in group A, 
ranging from 30-40 mm Hg. However 60% of the dogs examined in group B (dogs 12, 
14, 16, 19 and 20), showed slightly elevated ETC02 readings ranging from 30-48 mm Hg.
49
(2h uiui) ajnssajy poqg pusuy
50
FIG
 
6: 
Pl
ot
 o
f 
me
an
 
pu
lse
 
rat
e 
+/-
 S
EM
 
(b
ea
ts
/m
in
ut
e)
 v
er
su
s 
tim
e 
(h
ou
rs
) 
for
 d
og
s 
in 
gr
ou
p 
A 
and
 
gr
ou
p 
B.
 
Gr
ou
p 
A 
(N
o 
1-
10
) 
re
ce
iv
ed
 
flu
ni
xi
n,
 1
.1 
m
g/
kg
, 
i.v
., 
du
rin
g 
an
ae
st
he
sia
, 
pr
ior
 t
o 
the
 
sta
rt 
of 
su
rg
er
y.
Gr
ou
p 
B 
(N
o 
11
-2
0)
 r
ec
eiv
ed
 
flu
ni
xi
n,
 l
.lm
g/
kg
, 
i.v
., 
aft
er
 a
na
es
th
es
ia
 
had
 
te
rm
in
at
ed
.
Q .
oa
(N
<n
(N
00o
o
00
©
<N
T T
edosz
8
ooo S o  oT f CN o00 o oCN
(sinuiui/sjBoq) 7+ ospviinraw
51
SE
M 
= 
St
an
da
rd
 
err
or
 o
f 
me
an
 
Pre
 
= 
Pr
ior
 t
o 
in
du
ct
io
n 
of 
an
ae
st
he
si
a
FIG
 
7: 
Pl
ot
 o
f 
the
 
me
an
 
re
sp
ira
to
ry
 
ra
tes
 
+/-
 S
EM
 
(b
re
at
hs
/m
in
ut
e)
 
ve
rs
us
 t
im
e 
(h
ou
rs
) 
for
 d
og
s 
in 
gr
ou
p 
A 
and
 
gr
ou
p 
B.
 
Gr
ou
p 
A 
(N
o 
1-
10
) 
re
ce
iv
ed
 
flu
ni
xi
n,
 l
.lm
g/
kg
, 
i.v
., 
du
rin
g 
an
ae
st
he
sia
, 
pr
ior
 t
o 
the
 
sta
rt 
of 
su
rg
er
y.
Gr
ou
p 
B 
(N
o 
11
-2
0)
 r
ec
eiv
ed
 
flu
ni
xi
n,
 l
.lm
g/
kg
, 
i.v
., 
aft
er
 a
na
es
th
es
ia
 
had
 
te
rm
in
at
ed
.
I
ij
i
I
ex
6060
o .
oO
COo»oO CNoo
3O
4>
B
P
CNN-O
CN
©
o
o
(3jnuiui/sqiB3jq) uoneiidsd>{ uwjv
52
SEM
 
= 
Sta
nd
ard
 
err
or 
of 
me
an
 
Pre 
= 
Pr
ior
 t
o 
ind
uc
tio
n 
of 
an
ae
sth
es
ia
3.1.2 Biochemical param eters
Refer to appendix B, table B1 for normal canine biochemistry values. Tables B3 and B4 
shows the individual biochemistry parameters for dogs in group A and group B 
respectively, taken prior to the start o f anaesthesia, and again 12 and 30 hours after 
flunixin administration. Table B2 gives the biochemical profile o f each individual dog in 
the control group C (trial no's: C1-C10), taken at the same time points, as dogs in group A  
and B. There was no significant difference between the mean age, weight, anaesthetic or 
surgical times, between dogs in control group C, and dogs in group A and B. Table 8, 9 
and 10, shows the mean biochemical values ± SEM, for dogs in group A, group B and 
group C respectively, at 0, 12 and 30 hours after flunixin administration. No biochemistry 
was performed on Dogs 1 and 3, as the volume o f blood collected was only adequate to 
allow pharmacokinetic analysis o f flunixin.
When the biochemical values obtained from the 3 groups o f dogs (group A, group B and 
group C) were analysed statistically, it was found that there was no significant difference 
in any o f the parameters except for blood urea nitrogen (BUN). A significant increase (P < 
0.05) in the difference in the BUN values from 0 hours to 12 hours (2.7 mmol/1; 1.09 
mmol/1), and from 12 hours to 30 hours (-1.04 mmol/1; -0.55 mmol/1), in dogs in group A  
and group B respectively i.e. dogs that had received flunixin as an analgesic, was seen, 
when compared with dogs in group C (0.71 mmol/1; -0.72 mmol/1) Le. dogs that had not 
received flunixin. However, there was no significant difference in the changes in BUN  
levels from 0 to 12 hours (2.7 mmol/1) and 12 to 30 hours (-1.04 mmol/1), between dogs in 
group A, when compared to dogs in group B (1.09 mmol/1, -0.55 mmol/1). There was 
however a significant difference (P = 0.011) in the change in BUN levels from 0 to 30 
hours (1.67 mmol/1) in dogs in group A, while dogs in group B (0.47 mmol/1) and group C 
(0.01 mmol/1) showed no significant difference.
In case o f group A dogs, numbered 1, 4, 5, 7 and 8, the initial rise in BUN levels 12 hours 
after flunixin administration had decreased by 30 hours. Dog 2, showed a large increase in 
BUN, serum creatinine and phosphate levels 12 hours after flunixin administration, 
suggesting possible renal damage. This maybe due to the fact that this dogs blood pressure 
was on the low side (63-75 mm Hg) throughout anaesthesia. Its blood pressure only rose 
to above 80 mm Hg after anaesthesia had been terminated. As no 30 hour blood sample 
was taken, one cannot say if  these parameters continued to rise or whether they returned 
to normal levels. The dog however made an unremarkable recovery and was exceedingly
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Table 8: Mean biochemical values o f dogs in group A ± SEM, taken prior to flunixin 
administration, and then 12 and 30 hours after its administration. Dogs in group A (trial no 
1-10), received flunixin 1.1 mg/kg, Lv., during anaesthesia, prior to the start o f surgery.
0 hours 12 hours 30 hours
Biochemical parameters Mean SEM Mean SEM Mean SEM
Urea (mmol/1) 4.53 0.45 7.24 0.535 6.20 0.34
Creatinine (umol/1) 93.00 7.37 114.30 11.30 98.75 4.83
Phosphate (mmol/1) 1.49 0.17 1.58 0.15 1.57 0.13
Total protein (g/1) 57.29 1.87 57.67 2.1 54.57 2.81
Albumin (g/1) 28.71 1.38 27.22 1.53 27.14 1.44
Globulin (g/1) 28.57 2.77 30.44 1.85 27.43 3.23
Sodium (mmol/1) 147.13 0.48 146.89 1.06 147.75 1.11
Potassium (mmol/1) 4.42 0.14 4.46 0.15 4.28 0.17
Chloride (mmol/1) 114.50 1.12 113.22 1.10 115.71 1.9
Table 9: Mean biochemical values o f dogs in group B ± SEM, taken prior to flunixin 
administration, and then 12 and 30 hours after its administration. Dogs in group B (trial no 
11-20), received flunixin 1.1 mg/kg, Lv., after anaesthesia had terminated.
0 hours 12 hours 30 hours
Biochemical parameters Mean SEM Mean SEM Mean SEM
Urea (mmol/1) 4.29 0.21 5.34 0.29 4.76 0.72
Creatinine (umol/1) 84.90 5.74 87.80 6.58 89.30 7.4
Phosphate (mmol/1) 1.63 0.11 1.48 0.09 1.54 0.08
Total protein (g/1) 53.40 1.76 52.56 1.83 56.00 1.80
Albumin (g/1) 26.30 0.50 26.44 0.71 28.60 0.73
Globulin (g/1) 27.10 1.50 26.11 1.48 27.80 1.66
Sodium (mmol/1) 147.30 0.50 147 1.09 147.10 0.48
Potassium (mmol/1) 4.46 0.08 4.79 0.12 4.69 0.11
Chloride (mmol/1) 112.90 0.62 113.30 0.83 111.33 1.55
Table 10: Mean biochemical values o f dogs in group C ± SEM, taken prior to anaesthesia, 
and then 12 and 30 hours after its termination. Dogs in group C (trial no C1-C10), received 
no flunixin, intra or post-operatively.
0 hours 12 hours 30 hours
Biochemical parameters Mean SEM Mean SEM Mean SEM
Urea (mmol/1) 5.26 0.52 4.55 0.44 5.27 0.50
Creatinine (umol/1) 93.80 5.82 89.60 4.56 94.40 4.59
Phosphate (mmol/1) 1.46 0.11 1.46 0.13 1.53 0.16
Total protein (g/1) 62.70 1.43 60.10 1.26 62.10 1.99
Albumin (g/1) 32.60 1.22 31.20 1.27 31.60 1.41
Globulin (g/1) 30.00 1.26 28.90 1.35 30.50 1.85
Sodium (mmol/1) 148.90 0.48 146.70 1.35 145.80 0.55
Potassium (mmol/1) 3.90 0.11 4.45 0.20 4.56 0.19
Chloride (mmol/1) 111.70 1.37 110.00 1.19 108.80 1.65
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bright with an excellent appetite throughout. No clinical evidence o f kidney damage such 
as polyuria or polydipsia was reported by the owner. In dog number 8, the owner 
expressed concern regarding her dog being excessively thirsty after surgery for almost 2 
months. This dog's blood urea and creatinine levels had risen 12 hours after flunixin 
administration. Its initial BUN level, prior to flunixin was 6.3 mmol/1, which increased to
8.7 mmol/1, 12 hours after flunixin administration. However, 30 hours later all values 
though still high were falling (8.1 mmol/1). It was decided to retake a blood sample 2 
months after flunixin administration. Blood urea, creatinine and phosphate levels were 
found to be back to their original values prior to flunixin administration (4.1 mmol/1; 88 
umol/1; 1.06 mmol/1 respectively).
In case o f dog trial numbers 6, 9 and 10, the BUN levels were still high at 30 hours. In 
dog number 10, another 3 blood samples were taken 15 days, 2 and 5 months after 
flunixin administration. Prior to flunixin administration, the dog's BUN was 3.6 mmol/1, 
which rose to 6.2 mmol/1 12 hours after flunixin administration, and had further increased 
to 6.8 mmol/1, at 30 hours. Plasma phosphate levels had also risen from 1.29 mmol/1 (pre), 
to 1.63 mmol/1 (12 hours), and 1.7 mmol/1 (30 hours). The plasma creatinine levels 
however had fallen from 127umol/l (pre), 125 umol/1 (12 hours) and 100 umol/1 (30 
hours). On day 15, the dog's BUN remained high at 6.6 mmol/1, but the plasma phosphate 
levels had returned to base level (1.21 mmol/1). 2 months later the BUN level showed a 
further rise and was 7.9 mmol/1. Inspite of this rise in blood urea level, the dog did not 
show any clinical signs o f kidney damage. Five months later, a follow-up blood sample 
was taken and the BUN level had started to fall (7.4 mmol/1), but was still on the high side 
of normal. Both plasma phosphate (1.2 mmol/1) and plasma creatinine levels (113 umol/1) 
were back to their original basal levels before flunixin administration.
In all dogs in group B the rise in blood urea levels seen 12 hours after the flunixin injection 
had started to decrease to the pre-flunixin levels by 30 hours after flunixin administration. 
The only exception was in dog numbers 12 and 20. In dog number 12, the rise in BUN  
level at 30 hours post flunixin, was only slightly greater than at 12 hours. However, in dog 
20, there was quite a large rise in the BUN, compared with 12 hours post flunixin, and a 
marginal increase in plasma creatinine and phosphate levels. The dog showed no clinical 
signs o f renal damage. In the post-operative period regular contact with the owner was 
maintained, and the dog did not exhibit signs o f polyuria or polydipsia. This animal was 
due back 10 days after the administration o f anaesthetic, for suture removal. However, as 
the dog was doing so well, its owner had her own veterinarian remove the stiches, and
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hence no follow-up blood sample was taken. Dog 15, had follow-up blood samples taken 
at 15 days, 1 month and 2 months after flunixin administration. The BUN level was found 
to stay low, and at 2 months post flunixin, was exactly the same value as it was prior to 
flunixin administration.
All other biochemical parameters analysed statistically, namely creatinine, phosphate, total 
protein, albumin, globulin, sodium, potassium and chloride, showed no significant 
difference between the 3 groups o f dogs, from 0 hours to 12 hours and 12 hours to 30 
hours post flunixin.
3.2 PLASMA DISPOSITION AND PHARMACOKINETICS
3.2.1 HPLC method - Evaluation of sensitivity and precision of the technique
Refer to appendix C, table C l, for the intra-assay coefficient o f variation and table C2 for 
the inter-assay coefficient o f variation. The mean plasma concentrations ± standard error 
of the mean (SEM) are given in table C3, for dogs in group A (trial numbers 1-10) and 
table C4 for dogs in group B (trial numbers 11-20).
The limit o f detection o f flunixin meglumine in plasma by the HPLC technique used was 
0.03 (ig/ml. The mean percentage recovery o f the drug flunixin was 81.5 %, extending 
over a range o f approximately 10%. The coefficient o f variation was less than 11% (Refer 
to table 11). The degree o f variation between the 20 assays (dogs 1-20), performed on 
different days, was determined by the inter-assay coefficient o f variation or 'between days' 
variation. The mean percentage recovery o f flunixin was 82.2%, extending over a range o f  
approximately 11%. The coefficient o f variation was less than 20% (table 11).
3.2.2 Chromatograms
Flunixin meglumine was well chromatographed, with no odd peaks or interfering peaks. 
The retention time was 6.5 minutes. The typical chromatogram is presented in figure 8.
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Table 11:
The intra-assay and inter-assay variations o f the mean % recovery o f flunixin, and the 
coefficient o f variation for flunixin, for each spike concentration used in the HPLC 
extraction procedure.
Spike Mean % recovery of flunixin Coefficient of variation (%)
Cone Intra-assay variation Inter-assay variation Intra-assay variation Inter-assay variation
0.25 ug/ml 76.5 79.9 8.6 19.9
1 ug/ml 83.8 76.8 7.1 13.6
2 ug/ml 80.2 79.4 6.5 10.3
5 ug/ml 83.5 84.9 10.7 10.4
10 ug/ml 84.4 87.1 3.0 10.0
Mean 81.5 82.2 7.4 12.6
ABBREVIATIONS
Cone = concentration 
% = percentage
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Figure 8: Flunixin chromatography
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EXPERIMENT CODE: Flunixin dog No 19,
Date of collection of blood: 12/5/93,
Date of extraction and injection of drug: 21/5/93,
Solvent: Me0H:H20 70:30, Perchloric Acid=400pl/100ml,
Flow rate: lml/min, Column: C8 with guard, Detector: spectra 100,
Pump: LS isochrome, Wave length: 287nm, Injection volume: 15pi,
Loop volume: 20pl,
Standard concentration: lOpg/ml,
Absorbance: 0 01, Analysis time: 5 min,
Graph speed: 30cm/hour, Amplification: lOmV
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3.2.3 Recovery
The mean percentage recovery o f flunixin from canine plasma was 82.2% (range=ll%) 
(table 11). The mean plasma concentration profile o f flunixin, together with the standard 
error o f the means versus time, after flunixin injection, in dogs in group A  and group B, 
are shown in table 12, and is represented graphically in figure 9. In dog number 7, two 
blood samples taken at 48 and 60 hours, showed no flunixin. Flunixin was detected up to 
30 hours in all dogs, except for numbers 3 and 8 in group A, and numbers 11 and 17 in 
group B. In dogs numbers 3, 8 and 11, flunixin was detected for up to 24 hours only. In 
dog number 17 flunixin was last detected in the plasma 12 hours after its administration.
Peak plasma concentrations seen within the first 2 minutes after the drug's administration, 
ranged from 38.57 (ig/ml to 18.14 fig/ml, with a mean concentration o f 24.48+1.84 fxg/ml, 
for dogs in group A. Similarly in dogs in group B, peak plasma concentrations ranging 
from 41.16 (ig/ml to 16.77 pg/ml, with a mean concentration o f 28.71 + 2.11 pg/ml were 
seen within the first 2 minutes. In both groups o f dogs, there was a steady drop in plasma 
concentration o f the drug for 10 minutes after its administration, following which there 
was little or no change in the plasma concentration until 30 minutes after administration, 
when once again plasma levels started to fall steadily. In dogs numbers 1, 3, 7, 13, 15, and 
16 in group B, there was a slight rise in the plasma concentration o f  the drug, during this 
period. There was no significant difference in the plasma concentrations at 2 minutes, or 
12, 24 and 30 hours post drug administration, between dogs in group A and group B. The 
plasma concentration o f flunixin at 30 hours, in dogs in both groups, was 0.07 + 0.02 p. 
g/ml. The semi-logarithmic plot o f the mean plasma concentrations o f flunixin o f dogs in 
groups A and B versus time (figure 9) were very similar.
3.2.4 Pharmacokinetics
The pharmacokinetic parameters used to describe the plasma flunixin concentration versus 
time data, when compartmental analysis o f data was performed in the individual dogs, are 
given in appendix D, table D l, for dogs in group A (trial numbers 1-10), and table D2 for 
dogs in group B (trial numbers 11-20).
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Table 12: Mean plasma concentration o f flunixin, together with the standard errors o f the 
means versus time, after an intravenous injection o f  flunixin, in dogs in group A  and group B.
Group A dogs (trial no's 1-10) received flunixin, 1.1 mg/kg, i.v., during anaesthesia, prior to the 
start o f surgery.
Group B dogs (trial no's 11-20) received flunixin, 1.1 mg/kg, Lv., immediately after surgery and 
anaesthesia had been terminated.
Time (hour) Mean plasma concentration 
Group A
(ug/ml)
SEM 
Group A
(ug/ml)
Mean plasma concentration 
Group B
(ug/ml)
SEM 
Group B
(ug/ml)
Pre 0 0 0 0
(2 min) 0.03 24.48 1.84 28.71 2.11
(5 min) 0.08 18.00 1.43 21 .34 1.47
(10 min) 0.17 13.36 0.78 16.65 1.14
(15 min) 0.25 11.81 0.84 14.57 0.99
(20 min) 0.33 11.16 0.86 13.62 0.89
(30 min) 0.50 10.06 1.04 12.20 0.91
(45 min) 0.75 8.73 0.81 9.89 0.86
1 7.55 0.78 8.40 0.69
1.5 5.56 0.84 5.93 0.70
2 4.32 0.46 4.11 0.48
4 2.07 0.48 1.73 0.39
6 1.23 0.45 0.84 0.16
8 0.86 0.25 0.57 0.12
10 0.67 0.19 0.41 0.07
12 0.47 0.12 0.32 0.06
20 0.23 0.06 0.19 0.04
24 0.21 0.06 0.11 0.02
30 0.07 0.02 0.07 0.02
ABBREVIATIONS
Pre = Prior to flunixin administration
min = minutes
SEM = Standard error of mean
ug/ml = micrograms per millilitre
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Plasma concentrations up to 30 hours were used to calculate the pharmacokinetic 
determinants. Compartmental as well as non-compartmental analyses o f  the plasma 
flunixin concentration, for dogs in groups A and B were performed. When the plasma 
concentration o f flunixin was analysed by compartmental model analysis, the plasma 
flunixin disposition was best described by a tri-exponential decline curve in all dogs except 
numbers 6 and 16, where a bi-exponential equation was found to provide a better fit, as 
determined by using Akaike Inverse square o f the concentrations to obtain the best fit 
model. The mean pharmacokinetic parameters ±  SEM, o f plasma flunixin obtained after 
compartmental analysis o f data, for dogs in groups A and B, are shown in table 13. The 
mean elimination half-life o f flunixin in dogs in group A, was 7.86 + 1.18 hours (table 13), 
while in group B, it was 6.10 + 0.74 hours (table 13). These were not significantly 
different. The mean area under the plasma concentration versus time curve for observed 
values (AUCob), for dogs in group A (35.7 ±  5.3 ug.hr/ml) and B (33.4 + 3.3 ug.hr/ml), 
were similar. In group A, the mean total body clearance (CLb) was 34.88 ± 5 .6 4  ml/kg.hr, 
volume o f central compartment (Vc) was 34.58 ± 2.58 ml/kg, and apparent volume o f  
distribution at steady state (Vdss) was 195.89 ± 38.5 ml/kg. Group B, had a mean CLb of 
34.55 + 4.58 ml/kg.hr, Vc o f 32.49 ±  4.43 ml/kg, and a mean Vd(ss) o f 132.63 ±  8.73 
ml/kg. The mean elimination rate constant (Kel), in group A was 0.96 ± 0.09 per hour, 
and in group B it was 1.16 ± 0.17 per hour. There were no significant differences between 
the mean values obtained for CLb, Vc, Vdss, and Kel, for dogs in groups A  and group B.
Non-compartmental analysis o f the flunixin plasma concentration data for dogs in groups 
A and B, enabled the calculation o f the area under zero moment curve (AUC), area under 
first moment curve for observed values (AUMCob), and mean residence time (MRT). 
Refer to appendix D, table D3 and D4, for individual results. Table 14 shows the mean ± 
SEM, o f the same. The mean AUMCob for dogs in group A was 334.79 ± 94.5 (ig.h^/ml, 
giving a mean MRT o f 8.73 + 2.53 hours, while for dogs in group B, the mean AUMCob 
was 161.15 + 23.9 fig.h^/ml, giving a mean MRT of 4.52 + 0.36 hours. Statistically, 
neither the mean AUMCob nor the mean MRT, o f dogs in group A, was significantly 
different to that in group B. In addition, there was no significant difference between mean 
CLb (35.93 ± 5.96 ml/kg.hr) or Vdss(ob) (303.4 + 94.8 ml/kg) for dogs in group A, when 
compared with dogs in group B (CLb=34.84 + 3.93 ml/kg.hr, Vdss(ob)=152.8 + 16.4 
ml/kg).
When the lowest mean arterial blood pressure reading o f each dog in the trial was plotted 
graphically against the elimination half life (Figure 10) and mean residence time
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Table 13: Mean pharmacokinetic parameter +/- SEM. obtained after compartmental 
analysis o f plasma flunixin concentration versus time data, for dogs in groups A  and B
Group A dogs (trial no's 1-10) received flunixin, 1.1 mg/kg, i.v., during anaesthesia, prior to the 
start of surgery. Group B dogs (trial no's 11-20) received flunixin, 1.1 mg/kg, i.v., immediately 
after surgery and anaesthesia had been terminated.
Pharmacokinetic
variables
UNITS Group A SEM 
Group A
Group B SEM 
Group B
1/2 LIFE P (distribution) hrs 0.05 0.01 0.16 0.12
1/2 LIFE A (distribution) hrs 0.90 0.12 0.76 0.08
1/2 LIFE B (elimination) hrs 7.86 1.18 6.10 0.74
CPO ug.hr/ml 33.45 2.52 37.38 3.08
AUC ug.hr/ml 38.20 5.08 35.72 3.45
AUC ( observed) ug.hr/ml 35.65 5.24 33.40 3.27
Vc ug/kg 34.58 2.58 32.49 4.43
Vd (ss) ml/kg 195.89 38.50 132.63 8.73
CL(b) ml/kg.hr 34.88 5.64 34.55 4.58
K el /hr 0.96 0.09 1.16 0.17
Table 14: Mean pharmacokinetic parameter +/- SEM. obtained after non-compartmental 
analysis o f plasma flunixin concentration versus time data, for does in groups A and B
Pharmacokinetic
variables
UNITS Group A SEM 
Group A
Group B SEM 
Group B
AUC ( observed) ug.hr/ml 38.71 6.10 34.61 3.15
AUMC (observed) ug.hmnl 334.79 94.50 161.15 23.90
MRT hrs 8.73 2.53 4.52 0.36
Vd (ss) ml/kg 303.40 94.80 152.80 16.40
CL(b) ml/kg.hr 35.93 5.96 34.84 3.93
ABBREVIATIONS
SEM
1/2 LIFE P (distribution) 
1/2 LIFE A (distribution) 
1/2 LIFE B (elimination) 
CPO 
AUC
AUC ( observed)
AUMC (observed)
Vc
Vd (ss)
CL(b)
K el
MRT
= Standard error of means 
= Distribution half life 
= Distribution half life 
= Elimination half life
= Initial concentration of drug in plasma, following an intravenous injection 
= Area under zero moment curve 
= Area under the curve (observed values)
= Area under the first moment curve (observed)
= Apparent volume of central compartment 
= Apparent volume of distribution at steady state 
= Body clearance of drug 
= Elimination rate constant 
= Mean residence time 63
(Figure: 11) o f flunixin in the plasma o f that dog, no correlation between the two could be 
seen. Table 15, shows the lowest arterial blood pressure readings recorded in each dog 
during anaesthesia, together with the elimination half-lives and MRTs o f the individual 
dogs. Tables 16 and 17 illustrate the elimination half-lives and MRTs in ascending order 
to demonstrate more clearly the relationship between mean arterial blood pressure and 
elimination o f flunixin from the body.
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Table 15: Lowest mean arterial blood pressure reading o f each dog in 
the trial (No : 1-20), versus elimination half life and mean residence time 
(MRT) o f plasma flunixin, in that dog.
Dogs no 1-10 (group A) received flunixin, 1.1 mg/kg iv, during anaesthesia, 
prior to the start o f surgery. Dogs no 11-20 (group B) received flunixin, 
1.1 mg/kg iv, immediately after anaesthesia terminated.
Trial
No
Lowest BP 
(mmHg)
Elimination half life 
(Hours)
MRT
(Hours)
1 . 52 9.70 4.49
2 60 7.73 6.94
3 . 78 11.86 30.40
4 . 68 4.75 6.37
5 59 15.40 7.71
6 40 3.83 4.83
7 48 9.48 12.36
8 55 5.76 4.72
9 78 5.64 6.32
10 57 4.47 3.19
11 58 3.76 3.32
12 47 8.29 3.85
13 74 .. 9.53 6.09
14 57 5.64 6.35
15 74 5.48 5.29
16 52 ■ 5.37 3.69
17 71 3.59 4.98
18 62 5.12 3.52
19 60 4.66 3.26
20 53 ; 9.58 4.87
ABBREVIATION
BP = Blood pressure
MRT = Mean residence time
mm Hg = Millimeters of mercury
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Table 16: Elimination half life ('hours') of flunixin. in all dogs in the trial (No 1-201, together with
the lowest arterial blood pressure readings recorded in these dogs during anaesthesia The table 
has been arranged in ascending order of the elimination half lives.
Dog 
Trial Number
Elimination half life 
(Hours)
Lowest BP 
(mmHg)
17 3.59 71
11 3.76 58
6 3.83 40
10 4.47 57
19 4.66 60
4 4.75 68
18 5.12 62
16 5.37 52
15 5.48 74
9 5.64 78
14 5.64 57
8 5.76 55
2 7.73 60
12 8.29 47
7 9.48 48
13 9.53 74
20 9.58 53
1 9.70 52
3 11.86 78
5 15.40 59
FIG 10: Graphical representation of the above table.
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ABBREVIATIONS
BP = Blood pressure
mm Hg = Millimeters of mercury 66
Table 17: Mean residence time (hours) of flunixin, in all dogs in the trial (No 1-20), together with 
the lowest arterial blood pressure readings recorded in these dogs during anaesthesia. The table has 
been arranged in ascending order of the mean residence time (MRT).
Dog 
Trial No
MRT
(Hours)
Lowest Blood Pressure 
(mmHg)
10 3.19 57
19 3.26 60
1 1 3.32 58
18 3.52 62
16 3.69 52
12 3.85 47
1 4.49 52
8 4.72 55
6 4.83 40
20 4.87 53
17 4.98 71
15 5.29 74
13 6.09 74
9 6.32 78
14 6.35 57
4 6.37 68
2 6.94 60
5 7 71 59
7 12.36 48
3 30.40 78
FIG 11: Graphical representation of the above table.
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ABBREVIATION
BP = Blood pressure
mm Hg = Millimeters o f mercury
MRT = Mean residence time
4. DISCUSSION
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The NSAID flunixin meglumine has been used increasingly in veterinary clinical practice 
as a post-operative analgesic. Reid and Nolan (1991), found it to be as effective as the 
opioid papavertum in controlling the acute pain associated with surgery, and although 
analgesia was not evaluated in this study, all the dogs appeared comfortable in the post­
operative period.
Flunixin was administered intravenously at a dose rate o f 1.1 mg/kg, the dose licensed for 
use in the dog and recommended by Bottoms and colleagues (1983) and McKellar et al
(1989). This was also the dose used by Hardie et al (1985), in their pharmacokinetic 
studies on flunixin meglumine in conscious dogs.
4.1. P hysio log ical p a ram e te rs
Although no comparative study has yet been undertaken in the anaesthetised dog to 
establish whether or not the intra-operative use o f flunixin meglumine affects mean arterial 
blood pressure, pulse or respiration, Zellar and co-workers (1988), reported that a single 
intravenous dose o f flunixinin did not alter these parameters in the anaesthetised horse 
during surgery.
Mean pulse and respiratory readings o f dogs in group A were marginally lower than dogs 
in group B during anaesthesia, although this did not achieve statistical significance. When 
the dogs were considered individually, moderate tachycardia was seen in 3 animals (Dogs 
1,16 and 20). Dog 1 had a low blood pressure when the tachycardia started, and hence it 
may have been a compensatory mechanism On the other hand, it was just recovering from 
anaesthesia, and the tachycardia may have been the result o f pain. However, the dog 
seemed comfortable and recovery from anaesthesia was smooth. Dog 16, had a high heart 
rate to start with, and hence the fast heart rate seen during surgery was considered to be 
normal for that dog. The sudden increase in heart rate in dog 20 is difficult to explain. It 
may have been the result o f inadequate depth of anaesthesia.
In this study mean arterial blood pressures recorded in individual dogs were quite variable 
throughout the anaesthetic period and 45% of the dogs (5 from group A and 4 from group 
B), had mean arterial blood pressures falling below 60 mm Hg. Adequate cerebral and 
coronary perfusion is considered to require a mean systemic blood pressure greater than 
50 mm Hg (Haskins, 1987), and if  impairment is severe or if  the compensatory processes
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are exhausted, hypoperfusion develops (Haskins, 1987). However despite these low  
measured values all 9 dogs appeared to have good cardiovascular function, with good 
mucous membrane colour, capillary refill time and strong pulse volume in the peripheral 
arteries. On the basis o f clinical assessment, their condition gave no cause for concern.
Arterial blood pressure can be measured directly or indirectly, the more accurate method 
involving direct catheterization o f a systemic artery (Hamlin et al, 1982; Pettersen et al, 
1987). However as this was a study undertaken on healthy clinical cases, such an invasive 
technique could not be justified. Indirect methods o f arterial blood pressure measurements 
depend on occlusion o f a suitable artery by a pressure cuff and subsequent detection o f  
Korotkoff sounds or o f pressure oscillations as the cuff pressure fells from above systolic 
to below diastolic (Vincent et al, 1993). An alternative indirect method detects restoration 
o f flow or movement o f the arterial wall using the Doppler shift principle with an 
ultrasound source (Vincent et al, 1993).
In this study, blood pressure was measured indirectly using the Dinamap (Critikon). The 
Dinamap is designed for use in humans and uses the oscillometric principle (Kittleson and 
Olivier, 1983). It combines an automated inflation-deflation cycle with direct detection o f  
pressure oscillation (Sykes et al, 1991), and has systems to eliminate artefacts. It displays 
systolic, diastolic and mean arterial blood pressures, together with heart rate. The 
Dinamap is the most widely used indirect blood pressure monitor (Vincent et al, 1993). 
Vincent et al, (1993) mentioned that Ward (1990) (unpublished data), carried out a series 
o f preliminary tests using the Dinamap, and demonstrated impressive precision and 
reproducibility within dogs on different occasions, with the cuff applied to the tail. Ward
(1990) obtained highly variable results when the cuff was applied to a limb, but this may 
have been due to the feet that he used conscious dogs, and was therefore unable to keep 
the dogs sufficiently still while readings were being taken. Other workers have also 
investigated the accuracy o f indirect blood pressure measurements in the dog. Geddes and 
colleagues (1980) compared direct and indirect methods o f measuring mean arterial blood 
pressure in anaesthetized dogs, and found that indirect mean pressures correlated well 
with direct mean arterial pressure when the cuff width used was 43% o f the forelimb 
circumference. They measured mean pressures as low as 23 mm Hg, and observed that, 
when the correct sized cuff was applied to anaesthetised animals, the oscillometric method 
of measuring blood pressure was excellent, even at low blood pressure values. Weiser et 
al (1977) and Hamil et al (1982), reported good correlation between indirectly measured 
blood pressure and that obtained directly. Hamil et al (1982), found the Dinamap easy to
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apply, harmless to the dog, and accurate in dogs weighing between 7 kg and 52 kg. 
Therefore it appears that blood pressure can be measured accurately by non-invasive 
means in anaesthetised dogs if the correct sized cuff is used, and if  the dogs weigh more 
than 7 kgs. There is a conventional formula for the relationship between circumference o f  
the limb and cuff width, cuff width = 0.4 x limb circumference (Coulter and Keith, 1984). 
In dogs, narrow cuffs cause an overestimated measure o f arterial blood pressure while 
wide cuffs tend to underestimate the reading (Valtonen and Eriksson, 1970).
Before this study was undertaken, due consideration was given as to the siting o f the 
pressure cuff. Application to the tail necessitates removal o f hair from the tail base, a 
procedure which may not have met with owner approval. The limbs have a thinner hair 
coat which allows for easier pulse detection and as the lower forelimb was consistently 
easier to access during surgery, this was the chosen limb. Care was taken to measure the 
circumference o f the limb to which the cuff was applied, and to use a cuff o f the 
appropriate size. The limb was supported in the horizontal position and as all dogs 
weighed between 17 and 45 kg, which is within the range o f accurate measurement for the 
Dinamap, the arterial blood pressure readings obtained, were assumed to be accurate.
However mean arterial blood pressure readings did on occasions seem low in the absense 
o f clinical signs o f hypotension, and variability within individuals was a feature. Pettersen 
et al (1987), found that a linear relationship existed between blood pressure and heart rate 
when measured indirectly and directly, but noted that the indirect values were an 
underestimate o f the direct values. Their findings were similar to Coulter et a l (1981) who 
obtained much lower diastolic pressure readings with indirect readings compared with 
direct measurements. There seems to be no such report in the literature o f artefacts in the 
measurement o f systolic pressures, and so it may be more appropriate to measure this 
rather than mean blood pressure when using indirect methods o f measurement. Von 
Bergen et a l (1954) suggested that systolic blood pressure can easily, quickly, and most 
accurately be accomplished by oscillometry rather than by auscultation and palpation, and 
it is interesting to note that, in human clinical studies where the Dinamap is used, systolic 
blood pressure seems to be used for comparative purposes rather than mean arterial blood 
pressures. Irrespective o f the method and accuracy of its measurement, the importance o f  
monitoring arterial blood pressure and heart rate during anaesthesia lies in the ability to be 
able to detect changes in blood pressure rather than to determine the absolute values 
(Glen, 1970; Pettersen et al, 1987).
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The reasons for the low mean arterial blood pressure values measured in some dogs in this 
study are unclear. Blood loss during surgery, was not considered a possibility, as none o f  
these dogs bled excessively (>5%  body weight loss). In all these animals except one (dog 
12), the low blood pressure did not persist beyond 10-15 minutes. Dog 12, had a 
persistent low blood pressure for 1 hour 15 minutes. The reason for this is unknown, as 
the dog was not losing blood or excessive fluids during surgery, nor did the anaesthetic 
depth appear too deep. The low blood pressure may be a reflection o f the dog's natural 
resting blood pressure.
According to Vincent and colleagues (1993), the true resting arterial blood pressures in 
young healthy dogs may indeed be lower than previously believed and, like humans, there 
probably is an age-related rise in blood pressure. Initial data from 800 dogs indicated a 
significant age-related rise in blood pressure, as well as increases associated with obesity 
(Mitchell et al, 1993). In this study, all dogs were young and healthy, and hence the low  
blood pressure readings obtained may well be physiological. Much work has been 
published on canine blood pressure, but 'normal' indirect blood pressure values o f dogs as 
reported in one laboratory, seldom agree with those measured in another (Valtonen and 
Eriksson, 1970), thus making interpretation o f arterial blood pressure readings difficult. In 
addition to biological variation, arterial blood pressure in dogs is known to be affected by 
psychological factors (Muller, 1963) and by respiratory variation (Valtonen and Eriksson, 
1970). Anaesthesia, introduces several other variables, that make interpretation o f blood 
pressure even harder (Cullen, 1974). Many o f the drugs used for premedication, induction 
and maintenance o f anaesthesia decrease arterial blood pressure. It can also be affected by 
changes in PaC02 and body temperature, body position, blood volume, surgical 
stimulation and depth and duration o f anaesthesia (Cullen et al, 1972). NSAIDs have been 
shown to interfere with blood pressure control in hypertensive human patients (Durao et 
al, 1977; Watkins et al, 1980; Moore et al, 1981), but there is no evidence in veterinary 
literature to suggest that these drugs have a direct effect on arterial blood pressure in 
animals.
When arterial blood pressure falls during anaesthesia there is a decrease in both hepatic 
and renal blood flow which can affect the metabolism and excretion o f drugs. 
Consequently it could be expected that there might have been evidence o f higher flunixin 
plasma levels, prolonged whole body clearance, increased elimination half-lives and MRT 
in those dogs with the lowest recorded mean arterial blood pressures. However no such
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correlation was found to exist between low arterial blood pressure readings and plasma 
levels o f flunixin or the pharmacokinetics o f flunixin.
4.2 P h arm a co k in e tic s
Pharmacokinetic analysis provides a mathematical description o f drug disposition, usually 
in plasma. It provides useful information both on the rate o f drug passage into and its 
removal from the vascular compartment. Its importance to the clinician, lies in the fret that 
it gives a rational basis for selecting dosage schedules (Lees et al, 1990).
The fall in plasma flunixin concentrations was found to be tri-exponential except in dogs 6 
and 16, where it was bi-exponential. This was contrary to results reported by Hardie et al 
(1985), and McKellar et al (1991b). These workers recorded that the plasma 
concentration versus time curve best fitted a 2-compartmental model. The discrepancy 
with the study by Hardie et al (1985) is probably related to the fact that, Hardie et al 
(1985) only sampled for 12 hours and less intensively than in the present study where 
animals were bled for 30 hours. Similarly McKellar et al (1991b) sampled less intensively, 
especially within the first hour o f drug administration.
In this study, non-compartmental models were also used to analyse the concentration 
versus time data. Use o f non-compartmental models is based on the statistical moments 
theory (Cutler, 1978; Yamoka et al, 1978). The main advantages o f non-compartmental 
models over compartmental models, are firstly, that none o f the 'non-central' pools are 
identified with any anatomical structures (DiStefeno, 1982), and secondly, mathematical 
analyses o f time-varying kinetic data can be accomplished with integral equations, rather 
than differential equations, in contrast to multicompartmental analysis (DiStefano, 1982; 
DiStefano and Landaw, 1984). Semrad et al (1985) also used non-compartmental models 
to evaluate the pharmacokinetics o f flunixin in the horse, as they were unable to fit 
compartmental models to the experimental data. The use o f non-compartmental models 
were considered appropriate in this study particularly because o f the plateau effect seen 
from 1 0 -3 0  minutes after intravenous flunixin administration.
After the intravenous administration o f flunixin, high plasma concentrations were achieved 
immediately. In group A, the mean plasma drug concentration obtained at 2 minutes, was 
24.5 + 1.8 fig/ml, while in group B, it was 28.7 ± 2 .1  pg/ml. In dogs 1, 3, 7, 15, and 16, a
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slight rise in plasma fhmixin was seen, while in dogs 2, 4, 10, 13 and 18 a very marginal 
fall in plasma flunixin concentration was seen 10-30 minutes after the intravenous flunixin 
injection. This unusual decline curve with concentrations felling from maximum plasma 
values but then increasing again to minor peak values and subsequently declining was also 
described by McKellar et al (1991b), during their pharmacokinetic trials on flunixin given 
intravenously to beagles at 1.1 mg/kg. This rise, or lack o f fell, in plasma flunixin 
concentration from 10 minutes to approximately 30 minutes after flunixin administration 
may have been caused by enterohepatic circulation o f the drug. Duggan et a l (1975), and 
Risdall et al (1978), concluded that enterohepatic circulation o f NSAIDs is common in 
dogs while McKellar et a l (1991b), also felt that the pattern o f elimination o f flunixin in 
beagle dogs was consistent with enterohepatic cycling, although they did not indicate 
when the enterohepatic recirculation occurred. Lees and workers (1991), consistently 
noticed a small secondary peak in the plasma-concentration-time curve, when 
pharmacokinetic analyses o f 2.2 and 8.8 mg/kg flunixin i.v. was performed on calves and 
suggested that this was a consequence o f enterohepatic recirculation. Ivey (1986), 
suggested that enterohepatic recirculation and regeneration o f active drug, could cause 
prolonged local concentrations o f the drug in the intestinal mucosa, thereby producing 
local mucosal irritation. However, gastro-intestinal intolerance was not a feature of any of 
the dogs in this trial, probably because only a single dose o f flunixin at therapeutic levels 
was administered. Ivey (1986) suggested that enterohepatic circulation may prolong the 
half-life o f the drug. This was consistent with dogs 1, 2, 3, 7, and 13 whose elimination 
half-lives were prolonged, but not with dogs 4, 10, 15, 16 and 18 whose elimination half- 
lives were, in fact, less than the means for their particular group.
After the plateau effect, the rate o f decline o f the plasma drug concentration was reduced. 
The observed mean elimination half-life for dogs in group A (7.86 + 1.18 hours), was 
slightly longer, but not significantly so, than for dogs in group B (6.10 ±  0.07 hours). 
These results were higher than the 3.67 + 1.20 hours, reported by Hardie et al (1985) in 
intact awake mixed breed dogs given 1.1 mg/kg flunixin intravenously, and with those of 
McKellar et al (1991b) who administered i.v flunixin at the same dose to beagles (3.10 + 
0.85 hours). It is difficult to say whether the longer elimination half-life o f flunixin found 
in this study was due to anaesthesia, or whether in fact Hardie et al (1985), had 
underestimated the elimination half-life, because o f less sensitive assay and shorter blood 
sampling period. However, in support o f the work o f Hardie et al (1985), the 
pharmacokinetics o f flunixin in other conscious species were found to be similar. In 
lactating cattle the mean elimination half-life was 3.14 hours (Anderson et al, 1990), while
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in the horse it was o f much shorter duration (1.55 hours) (Chay et al, 1982). In the cat 
too, the mean elimination half-life was short (0.7 to 1.5 hours) (Taylor et al, 1991), 
however, in this study there were insufficient data points, which precluded the accurate 
calculation o f this parameter. The slower mean elimination half-life obtained in this study 
may suggest that anaesthesia does infact slow down the elimination o f flunixin as 
compared to conscious animals. However, until a parallel study in conscious dogs is 
carried out, no firm conclusions can be drawn. Such a study was not possible, in this trial. 
McKellar et al (1991b) found a short elimination half-life in beagles, but other workers 
(Runkel et al, 1972; Frey and Rieh, 1981; Frey and Loscher, 1985; Lee et al, 1990) have 
suggested that beagles demonstrate differences in drug pharmacokinetics when compared 
with mixed breed dogs. However, McKellar et a l (1989), suggested that the difference in 
flunixin pharmacokinetics between beagles and mixed-breed dogs is likely to be small, 
since their results in conscious beagles were similar to those o f Hardie et a l (1985) using a 
mixed breed group. Flower (1986) and Conlon (1988) found that renal elimination of 
NSAIDs is often pH dependent, with drug elimination occuring at a faster rate in alkaline 
urine. However, in this study no urine samples were collected, so this point could not be 
clarified.
The mean clearance o f the drug from the body, CL(b), in both groups A and B, was 
almost identical Le. 34.9 + 5.6 and 34.6 + 4.6 ml/kg.hr respectively. These values were 
half that reported by Hardie (63.6 +13.9 ml/kg.hr) and McKellar et al (1991b) (58.8 + 4.8 
ml/kg.hr). Considering the dogs individually, there were large variations. Clearance of 
flunixin was very quick in dog 5 (71.6 ml/kg.hr) and dog 17 (68.2 ml/kg.hr). The CL(b) 
values for dog 5 and 17, were consistent with that found to occur in awake dogs by 
Hardie et al (1985). Dog 9 had a slow CL(b) o f 15.7 ml/kg.hr. The variation in the 
clearance o f flunixin found in this study, correlates well with the observation made by 
Boothe (1989), who suggested that the clearance o f NSAIDs varies greatly among 
individuals within a species, thereby accounting for considerable variability in plasma half- 
lives o f these drugs. In this study, no correlation was found to exist between blood 
pressure and rate o f clearance o f the drug from the body.
The apparent volume o f the central compartment, Vc, found in groups A and B (34.58 + 
2.58 and 32.49 + 4.43 ml/kg) was half that found in Hardies study (78.8 + 17.9 ml/kg). 
The reason for this is unclear, but may reflect changes in cardiovascular function during 
anaesthesia. The volume o f distribution at steady state, Vdss, in group A was slightly, but 
not significantly higher than group B (195.89 + 38.5 and 132.63 + 8.73 ml/kg
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respectively). These results were comparable to Hardie's values o f 181 + 79 ml/kg, and 
those o f McKellar et al (1991b) (140 + 24 ml/kg).
4.3. B iochem istry
Stegelmeier and colleagues (1988), observed that in normal conscious dogs, administering 
flunixin meglumine at 1.1 mg/kg i.v., caused no severe side effects or gross lesions. They 
based this observation on a study o f  4 healthy dogs who were given flunixin 1.1 mg/kg 
Lv., for 3 days, and were then monitored clinically, together with urine and serum samples 
collected over a 72 hour period. All 4 dogs showed few physical or haematological 
changes. The dogs were euthanased after 72 hours and examined for gross and 
histological lesions. None were found.
Knodel and workers (1992), observed that acute renal failure could occur in any patient 
treated with NSAIDs, but felt that patients at greatest risk of developing acute renal 
failure from NSAIDs were those who required the vasodilating effects o f  prostaglandin to 
preserve renal blood flow and glomerular filtration. Crooks and Stevenson (1981) 
suggested that those healthy young patients who had suffered excessive blood loss during 
surgery, resulting in compromised renal perfusion, were most likely to develop this 
complication. It has been reported by Corcoran and Page (1943) and Glauser and Selkurt 
(1952), that anaesthesia in dogs depresses renal haemodynamics, reducing GFR and renal 
plasma flow. Rubin (1986), found that clinical and experimental conditions in which renal 
function was found to be prostaglandin dependent included low renal perfusion pressure 
induced by hemorrhagic shock, surgical stress and anaesthetic stress. Stillman et al (1984) 
and del Favero (1987) both mentioned anaesthesia as being one o f the factors which 
predisposes the animal to functional renal impairment during treatment with NSAIDs. 
Since the dogs in this trial were having both anaesthesia and surgery, and these are known 
to produce an increase in renal vascular resistance and a decrease in renal blood flow (Eng 
and Stahl, 1970; Rubin, 1986), they were, theoretically, at risk o f developing NSAID 
induced renal impairement.
As this was a clinical study, serum biochemistry, namely BUN, serum creatinine and serum 
phosphate, together with electrolytes, sodium, potassium and chloride, were used to 
identify changes in renal function in the individual animals, during the trial. These 
biochemical parameters were chosen, because BUN and plasma creatinine measurements
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are the time-honoured means o f estimating glomerular filtration rate (GFR) (Bovee and 
Joyce, 1979). Creatinine and urea are cleared from the blood primarily by glomerular 
filtration, and so their blood values are largely dependent on GFR (Bovee and Joyce, 
1979). Plasma creatinine is influenced little by factors other than glomerular filtration and 
is, therefore, a valuable means o f measuring GFR and renal function (Bovee and Joyce, 
1979). Creatinine is an end product o f muscle metabolism, and its end product is fairly 
constant and only slightly affected by protein intake, protein metabolism or physical 
activity (Bloch and Schoenheimer, 1939; Bleiler and Schedl, 1962). After its release from 
muscle, creatinine enters the plasma and is excreted almost entirely by glomerular filtration 
(Dominguez and Pomerene, 1945), and consequently, creatinine clearance can be used as 
a reasonable measure o f filtration rate (Bovee and Joyce, 1979). According to Narayanan
(1991), however, serum creatinine levels are not a good index for the early diagnosis o f  
acute renal failure. Urea is formed only in the liver and may be regarded as the end 
product o f protein catabolism, whether the protein is derived from dietary or tissue 
sources (Wills and Savory, 1981). BUN is, therefore, influenced by many factors other 
than glomerular filtration, principally nitrogen balance (Bovee and Joyce, 1979). For this 
reason, BUN does not reflect glomerular filtration as accurately as does serum creatinine 
(Bovee and Joyce, 1979). In patients with acute renal failure, however, there is a relatively 
good correlation between the severity o f illness and BUN concentrations (Wills and 
Savory, 1981).
More sensitive measures o f renal function are available. In addition to glomerular filtration 
rate (GFR) (Bovee and Joyce, 1979), effective renal plasma flow (ERPF) (Ram et al, 
1968) is an important and valuable index o f renal plasma flow. This is measured by the 
clearance o f para-aminohippurate (PAH) (Smith et al, 1945), and is a more sensitive 
method o f assessing renal function than BUN, but less sensitive than endogenous 
creatinine clearance (Smith et al, 1945). However, it is a time-consuming procedure, 
requiring urethral catheterization with its attendant risk o f infection, accurate sampling o f  
urine and blood and an i.v. infusion maintained at a constant rate over long periods (Ram 
et al, 1968). Because o f its complicated nature, it has remained a research procedure and 
is not used in clinical practice (Ram et al, 1968). A simplified clinical method for 
measurement o f ERPF is by using a single injection o f I125 Hippuran (Ram et al, 1968). 
This, however, requires the use o f radio-isotope labelled substance, which is impractical 
for routine renal assessment in veterinary medicine. The renal clearance o f creatinine, has 
been advocated for clinical measurement o f renal function (Finco, 1971; Bovee and Joyce, 
1979). Creatinine is excreted almost exclusively by glomerular filtration in the dog (Finco
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et al, 1981), so its clearance is used to estimate the GFR, but this method requires urethral 
catheterization to allow accurate measurements o f urine volume over a given period o f  
time. Since the dogs were young and known to be clinically normal prior to the start o f the 
trial, such an invasive procedure could not be deemed to be in the individual animal's best 
interest. Consequently this was not acceptable to the Home-Office. Other attempts to 
collect urine accurately over the required 3 hour period for creatinine clearance were 
found to be impractical. Hence, BUN, serum creatinine and serum phosphate levels, 
though not as sensitive or accurate as the above mentioned methods, were considered the 
most practical for this study.
There was a significant difference in the change in BUN levels from 0 to 12 hours in dogs 
that had received flunixin as an analgesic (Groups A and B), compared to those dogs 
which had not received flunixin (Control group C). This suggested that flunixin, and not 
anaesthesia and surgery, nor the time o f administration o f the drug, was responsible for the 
rise in BUN levels, thereby suggesting that flunixin may have caused some degree o f renal 
impairment, whether administered during or at the end o f anaesthesia. In general, 
anaesthesia appears to cause modest, readily reversible decreases in ERPF and GFR 
(Bastron, 1980), but prolonged deep anaesthesia can have profound depressant effects on 
renal circulation (Bovee and Joyce, 1979). In this study, it was not possible to study ERPF 
and GFR, but it was evident by the minimal changes o f BUN and serum creatinine levels in 
the control group, that anaesthesia and surgery alone caused few adverse effects. The 
marginal rise in serum creatinine levels in groups A, B and C, were probably caused by 
muscle damage incurred during surgery (Power et al, 1992). The changes in BUN levels in 
dogs in group A and B seen within the first 12 hours o f drug administration, are consistent 
with Stillman and Schlesingers (1990) observations, that the onset o f NSAJD-induced 
renal changes occur abruptly following initiation o f NSADD therapy.
In all dogs in group A, and in 8 dogs in group B (exceptions are dogs 12 and 20), BUN 
levels had begun to return to normal within 30 hours o f flunixin administration. Kore 
(1990) and Aronofl^ (1992) suggested that haemodynamic deterioration in renal function 
was often reversible after discontinuation o f NSAID therapy, and that rapid recovery (24- 
72 hours) o f baseline renal function generally occurred following discontinuation o f the 
drug. These findings were confirmed by Corwin and Bonventre (1984); Carmichael and 
Shankel (1985) and Brater (1990). The results o f this study were consistent with results 
reported by Blackshear and colleagues (1983), that the inhibitory effects o f  NSAIDs on 
renal cyclo-oxygenase weakened during 8 to 24 hours. There was still, however, a
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significant difference in the changes in BUN levels from 0 to 30 hours in dogs in group A 
when compared with changes in group C, while there was no significant difference in 
BUN levels from 0 to 30 hours in dogs in group B, when compared with group C. This 
suggests that the renal damage produced by flunixin in group A was greater than that 
produced in group B, providing support for the suggestion o f Smitherman (1992) that the 
risk o f renal damage caused by flunixin may be reduced if the drug is given when the dog 
is recovering from rather than during anaesthesia.
None o f the animals in this study appeared to develop serious renal impairment as a result 
of flunixin administration. Serious renal impairement was defined by Murray and Brater
(1990) as at least a doubling o f BUN or serum creatinine concentrations. This however, 
cannot be held true in all cases as shown below. In one dog (dog 4), BUN levels rose 
higher than 10 mmol/1 during the 30 hour period after flunixin administration. In Dog 4, 
the BUN level had more than doubled in 12 hours after flunixin administration, but by 30 
hours had begun to drop. This initial doubling o f BUN did not cause too much concern, 
however, as the level was still within the normal range for the dog. The highest rises in 
BUN, creatinine and phoshate were seen in dog 2 (group A) 12 hours after the drugs 
administration and dog 20 (group B) 30 hours after flunixin administration. The high 
BUN, creatinine and phosphate levels seen in dog 2 may have been due to the fact that this 
dogs blood pressure was on the low-side (63-75 mm Hg) throughout anaesthesia, and only 
rose to above 80 mm Hg after anaesthesia had been terminated. Over a range o f blood 
pressures from approximately 70 to 180 mm Hg there is normally very little change in 
either renal plasma flow or glomerular filtration rate (Bastron, 1980). Theoretically the 
administration o f flunixin during anaesthesia, when the blood pressure was lower than 70 
mm Hg, may have prevented PGE2  and PGI2  related vasodilation, causing a decrease in 
the rate o f renal plasma flow and glomerular filtration, with the development o f prerenal 
azotemia and renal damage from unopposed renal vasoconstriction. However, it is 
interesting to note that there was no direct correlation between the lowest recorded 
arterial blood pressure reading and a rise in BUN levels. The cause for the rise in BUN in 
this dog is, therefore, not clearly defined. Unfortunately no 30 hour sample was taken to 
know whether these levels had started to return to basal level. However, the dog made an 
unremarkable recovery and did not demonstrate any signs o f depression, anorexia, 
polyuria or polydipsia, suggestive o f clinical renal disease, at any stage. Dog 20, showed a 
sudden rise BUN, creatinine and phosphate levels at 30 hours. Throughout anaesthesia the 
animal's arterial blood pressure remained within the normal range and continued to remain 
within normal limits when flunixin was administered, at the end o f anaesthesia. No other
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drugs were given during the recovery period, which could have accounted for the sudden, 
unexpected rise in biochemical parameters. This dog underwent an ovario-hysterectomy, 
and in the correspondence relating to flunixin toxicity (Elswood, 1992), all the affected 
dogs underwent surgery for routine ovario-hysterectomy. Whether there is any 
connection, is difficult to say. This dog, however, showed no signs o f clinical renal disease 
and made an unremarkable recovery.
One owner (group A, dog 8), stated that her dog drank excessively for 2 months after 
surgery, but was otherwise bright, alert and had a good appetite. BUN and creatinine 
levels o f this dog measured 2 months after anaesthesia, were within the normal range, but 
the possible implications o f flunixin in the development o f the polydipsia and polyuria 
cannot be discounted.
In the 3 groups no other biochemical parameters examined, namely sodium, potassium or 
chloride, changed during the 30 hour trial period. This was not unexpected as all the dogs 
were normal healthy adults at the start o f the trial, and was consistent with the 
observations o f Brater (1988) and Whelton and Hamilton (1991). Brater (1988), 
concluded that, in most healthy patients, the risk o f sodium retention is low. Hyperkalemia 
can result from NSADD treatment but is an unusual complication o f NSAID treatment in 
healthy patients, presumably because o f the multiplicity o f factors that are capable o f  
maintaining potassium balance, even in the absence o f prostaglandins (Whelton and 
Hamilton, 1991). NSADD induced hyperkalaemia often occurs in the setting of NSAID 
induced acute renal deterioration or worsening o f underlying renal impairement (Whelton 
and Hamilton, 1991).
4.4 C onclusion
From this study, it may be concluded that flunixin meglumine is best avoided in the 
anaesthetised dog, but if required, should be administered on termination o f anaesthesia 
and surgery, rather than during anaesthesia and surgery. If administered to the 
anaesthetised dog, it is important to remember that the pharmacokinetics o f the drug may 
be altered in comparison to that reported in conscious dogs and consequently, the drug 
need not be repeated as often as required in the awake dog. Moreover, as flunixin is found 
to elevate BUN and creatinine levels in dogs under anaesthesia, it is strongly advised that 
no other nephrotoxic drug is administered simultaneously or for the next 30 hours after
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flunixin administration. Finally, flunixin should not be used in those animals known or 
suspected to have renal disease. While it has been stated that hypotension is best avoided 
during anaesthesia in those animals treated with NSAIDs as it increases the risk o f acute 
renal damage occuring (Bush et al, 1991), in this study, no correlation was found to exist 
between low mean arterial blood pressure readings and rise in BUN levels. Also, low mean 
arterial blood pressure readings during anaesthesia and surgery did not appear to alter the 
pharmacokinetics o f flunixin, and there was no correlation found between low mean 
arterial blood pressure readings, extended elimination half-life o f the drug and rise in 
BUN.
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APPENDIX A
TABLES
TABLE A l - Mean arterial blood pressure readings ± SEM of individual dogs in group A, 
taken every 5 minutes after induction o f anaesthesia, until the dog regained sternal 
recumbency.
TABLE A2 - Mean arterial blood pressure readings ± SEM o f individual dogs in group B, 
taken every 5 minutes after induction o f anaesthesia, until the dog regained sternal 
recumbency.
TABLE A3 - Pulse readings ± SEM of the individual dogs in group A, taken every 5 
minutes throughout anaesthesia.
TABLE A4 - Pulse readings ± SEM of the individual dogs in group B, taken every 5 
minutes throughout anaesthesia.
TABLE A5 - Respiratory rates (breaths/minute) ±  SEM of the individual dogs in group A, 
taken every 5 minutes throughout anaesthesia.
TABLE A6 - Respiratory rates (breaths/minute) ± SEM of the individual dogs in group B, 
taken every 5 minutes throughout anaesthesia.
TABLE A7 - ETC02 values (%) ± SEM o f dogs No 1, 2, 3, 8, and 9 (group A), taken 
every 5 minutes on commencement o f surgery, until termination o f anaesthesia.
TABLE A8 - ETC02 values (%) ± SEM of dogs No 11, 12, 14, 16, 17, 18, 19, and 20 
(group B), taken every 5 minutes on commencement o f surgery, until termination of 
anaesthesia.
FIGURES
FIGURE A l - Graphical representation o f mean blood pressure readings o f dogs No 1-5 
in group A versus time.
FIGURE A2 - Graphical representation o f mean blood pressure readings o f dogs No 6-10 
in group A versus time.
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FIGURE A3 - Graphical representation o f mean blood pressure readings o f dogs No 11- 
15 in group B versus time.
FIGURE A4 - Graphical representation o f mean blood pressure readings o f dogs No 16- 
20 in group B versus time.
FIGURE A5 - Graphical representation o f individual pulse readings o f dogs No 1-5 in 
group A versus time.
FIGURE A6 - Graphical representation o f individual pulse readings o f dogs No 6-10 in 
group A versus time.
FIGURE A7 - Graphical representation o f individual pulse readings o f dogs No 11-15 in 
group B versus time.
FIGURE A8 - Graphical representation o f individual pulse readings o f dogs No 16-20 in 
group B versus time.
FIGURE A9 - Graphical representation o f individual respiration readings o f dogs No 1-5 
in group A versus time.
FIGURE A10 - Graphical representation o f individual respiration readings o f dogs No 6- 
10 in group A versus time.
FIGURE A l l  - Graphical representation o f individual respiration readings o f dogs No 11- 
15 in group B versus time.
FIGURE A12 - Graphical representation o f individual respiration readings o f dogs No 16- 
20 in group B versus time.
FIGURE A13 - Graphical representation o f individual ETCO2  readings o f dogs No 1, 2, 
3, 8 and 9 in group A versus time.
FIGURE A14 - Graphical representation o f individual ETCO2  readings o f dogs No 11, 
12, 14, 16, 17, 18, 19 and 20 in group B versus time.
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Table A l: Mean arterial blood pressure +/- readings in mm Hg, of individual dogs in group A, 
taken every 5 minutes after induction of anaesthesia until the dog regained sternal recumbency. 
Dogs trial numbers 1-10 (group A), received flunixin meglumine, 1.1 mg/kg, i.v., during 
anaesthesia, prior to the start of surgery.
Mean arterial blood pressure readings in mm Hg
T rial No- 1 2 3 4 5 6 7 8 9 10 Mean BP SEM
Time
Pre 87 94 105 80 72 95 88.83 5.26
0 min 82 70 82 92 98 92 86.00 4.49
5 min 95 67 64 91 90 84 81.83 5.89
lO m in 75 86 64 68 86 85 79 77.57 3.66
15 min 80 86 93 82 89 84 79 84.71 2.05
20 min 75 95 69 82 84 86 57 78.29 5.10
25 min 85 102 65 40 74 84 81 71 75.25 6.83
30 min 72 100 65 70 78 83 85 93 80.75 4.50
35 min 60 98 75 73 72 87 88 79 75,25 16.56
40 min 60 100 59 74 65 89 86 76 72.38 7.04
45 min 83 68 75 70 55 90 92 80 76.63 4.64
50 min 75 82 68 75 93 55 83 96 78.44 4.39
55 min 62 69 85 92 64 72 65 78 83 74.44 3.74
1 hr 89 63 92 88 72 78 63 76 93 79.33 4.18
1 hr 5 min 70 63 82 90 72 80 55 59 92 73.67 4.69
1 hr 10 min 72 65 78 82 65 55 69 69.43 3.67
1 hr 15 min 52 69 86 95 60 48 55 94 69.88 7.27
1 hr 20 min 72 69 88 79 60 100 66 69 91 77.11 4.70
1 hr 25 min 69 70 92 80 74 89 84 60 94 79.11 4.12
1 hr 30 min 55 75 92 89 74 75 77 102 79.88 5.40
1 hr 35 min 55 65 90 108 62 68 70 97 76.88 7.16
1 hr 40 min 52 64 95 90 68 74 77 93 76.63 5.77
1 hr 45 min 64 68 94 98 77 74 79 94 81.00 4.85
1 hr 50 min 68 63 94 78 74 100 79.50 6.53
1 hr 55 min 68 60 94 72 72 86 75.33 5.56
2 hrs 70 78 95 84 76 78 80.17 3.82
2 hr 5 min 69 98 77 66 78 77.60 6.25
2 hr 10 min 71 85 82 68 76.50 4.77
2 hrs 15 min 79 80 79 70 77.00 2.71
2 hr 20 min 85 95 88 68 84.00 6.62
2 hrs 25 min 82 95 78 63 79.50 7.61
2 hr 30 min 79 84 75 79.33 3.19
2 hrs 35 min 72 66 69.00 4.24
2 hr 40 min 84 65 74.50 13.44
2 hrs 45 min 84 75 79.50 6.36
2 hr 50 min 66
2 hrs 55 min 74
3 hrs 78
3 hrs 5 min 70
3 hr 10 min 70
3 hrs 15 min 66
3 hr 20 min 68
3 hrs 25 min 79
3 hr 30 min 95
ABBREVIATIONS
Pre = Prior to induction of anaesthesia
Mean = Mean of the mean arterial blood pressure readings
SEM = Standard error of means
min = minute
mm Hg =  m illim eters of mercury
hr = hour
Table A l: Mean artenal blood pressure +/- readings in mm Hg, of individual dogs in group A, 
taken every 5 mmutes after induction of anaesthesia until the dog regamed sternal recumbency. 
Dogs tnal numbers 1-10 (group A), received flunixin meglumine, 1.1 mg/kg, i.v., dunng 
anaesthesia, prior to the start of surgery.
Mean arterial blood pressure readings in mm Hg
Trial No- 1 2 3 4 5 6 7 8 9| 10 Mean BP SEM
Time
Pre 87 94 105 80 72 95 88 83 5.26
0 min 82 70 82 92 98 92 86.00 4.49
5 min 95 67 64 91 90 84 81.83 5.89
10 min 75 86 64 68 86 85 79 77.57 3.66
15 min 80 86 93 82 89 84 79 84.71 2.05
20 rain 75 95 69 82 84 86 57 78.29 5.10
25 mm 85 102 65 40 74 84 81 71 75.25 6.83
30 min 72 100 65 70 78 83 85 93 80.75 4.50
35 min 60 98 75 73 72 87 88 79 75.25 16.56
40 min 60 100 59 74 65 89 86 76 72.38 7.04
45 min 83 68 75 70 55 90 92 80 76.63 4.64
50 min 75 82 68 75 93 55 83 96 78.44 4.39
55 min 62 69 85 92 64 72 65 78 83 74.44 3.74
1 hr 89 63 92 88 72 78 63 76 93 79.33 4.18
1 hr 5 min 70 63 82 90 72 80 55 59 92 73.67 4.69
1 hr 10 min 72 65 78 82 65 55 69 69.43 3.67
1 hr 15 min 52 69 86 95 60 48 55 94 69.88 7.27
1 hr 20 min 72 69 88 79 60 100 66 69 91 77.11 4.70
1 hr 25 min 69 70 92 80 74 89 84 60 94 79.11 4.12
1 hr 30 min 55 75 92 89 74 75 77 102 79.88 5.40
1 hr 35 mm 55 65 90 108 62 68 70 97 76.88 7.16
1 hr 40 min 52 64 95 90 68 74 77 93 76.63 5.77
1 hr 45 min 64 68 94 98 77 74 79 94 81.00 4.85
1 hr 50 min 68 63 94 78 74 100 79.50 6.53
1 hr 55 min 68 60 94 72 72 86 75.33 5.56
2 hrs 70 78 95 84 76 78 80.17 3.82
2 hr 5 mm 69 98 77 66 78 77.60 6.25
2 hr 10 min 71 85 82 68 76.50 4.77
2 hrs 15 min 79 80 79 70 77.00 2.71
2 hr 20 min 85 95 88 68 84.00 6.62
2 hrs 25 min 82 95 78 63 79.50 7.61
2 hr 30 min 79 84 75 79.33 3.19
2 hrs 35 min 72 66 69.00 4.24
2 hr 40 min 84 65 74.50 13.44
2 hrs 45 min 84 75 79.50 6.36
2 hr 50 min 66
2 hrs 55 min 74
3 hrs 78
3 hrs 5 min 70
3 hr 10 min 70
3 hrs 15 min 66
3 hr 20 min 68
3 hrs 25 min 79
3 hr 30 min 95
ABBREVIATIONS
Pre =  Prior to induction of anaesthesia
Mean = Mean of the mean arterial blood pressure readings
SEM = Standard error of means
mm =  mmute
mm Hg = millimeters of mercury 
hr =  hour
Table A2: Mean arterial blood pressure +/- SEM readings in mm Hg, of individual dogs in group B, 
taken every 5 minutes after induction of anaesthesia until the dog regained sternal recumbency. 
Dogs trial numbers 11-20 (group B), received flunixin meglumine, 1.1 mg/kg, i.v., immediately 
after anaesthesia had terminated
Mean arterial blood pressure readings in mm Hg
T rial No- 11 12 13 14 15 16 17 18 19 20 M ean BP SEM
Time
Pre 76 64 98 91 102 80 86 77 60 108 84.26 5.26
0 min 71 75 74 100 93 83 79 62 78 140 85.50 7.33
5 min 66 58 76 83 81 52 87 84 73 82 74.20 3.96
10 min 66 64 80 79 74 57 90 76 71 53 71.00 3.74
15 min 58 63 86 66 84 61 78 70 67 56 68.90 3.51
20 min 71 54 75 69 85 74 77 80 80 67 73.20 2.90
25 min 61 71 78 61 95 75 75 74 79 79 74.80 3.24
30m in 70 79 78 74 95 87 91 96 86 86 84.20 2.91
35 min 86 68 79 78 85 86 86 71 73 73 78.50 2.33
40 min 73 58 82 64 93 88 86 66 74 68 75.20 3.86
45 min 83 58 78 75 85 91 88 73 78 96 80.50 3.58
50m in 78 57 78 63 95 78 86 78 72 83 76.80 3.63
55 min 78 59 89 57 96 84 85 79 77 80 78.40 4.06
1 hr 70 59 84 69 92 77 79 72 72 76 75.00 2.99
1 hr 5 min 75 51 79 65 96 78 74 69 76 85 74.80 3.97
1 hr 10 min 72 51 82 66 93 58 71 78 71 80 72.20 4.03
1 hr 15 min 70 47 78 73 106 55 94 82 73 73 75.10 5.67
1 hr 20 min 78 53 86 72 59 93 78 72 75 74.00 4.35
1 hr 25 min 70 59 79 65 67 124 87 69 73 77.00 6.86
1 hr 30 min 73 58 85 80 56 100 72 79 73 75.11 4.73
1 hr 35 min 66 55 74 79 57 68 74 82 68.38 3.69
1 hr 40 min 68 57 89 66 74 75 87 73.71 4.66
1 hr 45 min 70 58 88 61 62 79 83 71.57 4.85
1 hr 50 min 65 55 83 70 66 60 73 67.43 3.72
1 hr 55 min 76 63 79 78 68 105 80 78.43 5.43
2 hrs 62 86 85 68 78 81 74 76.29 3.63
2 hr 5 min 66 72 75 70 79 81 85 75.43 2.72
2 hr 10 min 67 89 79 70 86 100 86 82.43 4.66
2 hrs 15 min 69 66 87 76 72 75 74.17 3.27
2 hr 20 min 70 72 81 102 83 90 83.00 5.31
2 hrs 25 min 81 57 70 94 85 79 77.67 5.72
2 hr 30 min 103 58 78 96 82 83.40 8.73
2 hrs 35 min 110 62 73 79 77 80.20 8.95
2 hr 40 min 100 55 80 81 80 79.20 8.00
2 hrs 45 min 62 76 77 71.67 5.93
2 hr 50 min 87 75 72 78.00 5.61
2 hrs 55 min 71 80 74 75.00 3.24
3 hrs 78 95 90 87.67 6.18
3 hrs 5 min 76 95 93 88.00 7.38
3 hr 10 min 78 88 83.00 7.07
3 hrs 15 min 92
3 hr 20 min 84
3 hrs 25 min 82
3 hr 30 min
ABBREVIATIONS
Pre = Prior to induction of anaesthesia min =  minute
Mean = Mean of the mean arterial blood pressure readings mm Hg = millimeters of mercury
SEM = Standard error of means hr = hour
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Table A3 : Pulse readings +/-SEM, in beats/minute, of the individual dogs in group A, 
taken every 5 minutes throughout anaesthesia.
Dogs trial numbers 1-10 (group A), received flunixin meglumine, 1.1 mg/kg, i.v., during 
anaesthesia, prior to the start of surgery.
Pulse readings in beats/minute
T rial No- 1 2 3 4 5 6 7 8 9 10 M ean SEM
Time
Pre 160 120 132 100 120 112 128 100 130 120 122.20 5.80
0 min 110 100 120 120 122 120 142 71 113.13 7.84
5 min 90 110 110 130 110 118 130 132 107 115.22 4.86
10 min 100 80 110 120 120 108 88 134 89 98 104.70 5.63
15 min 90 60 90 118 112 125 95 134 110 91 102.50 7.19
20 min 110 60 100 130 112 120 95 128 100 90 104.50 6.89
25 min 120 60 100 140 130 90 90 128 90 85 103,30 8.39
30 min 140 80 100 140 120 82 100 120 93 83 105.80 7.64
35 min 138 79 100 130 130 80 100 118 90 86 105.10 7.41
40 min 130 75 108 130 120 80 92 118 100 82 103.50 6.92
45 min 130 85 108 130 120 90 90 115 80 82 103.00 6.62
50 min 130 80 108 128 120 82 90 118 108 73 103.70 6.99
55 min 120 79 108 120 120 90 83 110 100 82 101.20 5.56
1 hr 110 80 102 120 115 90 83 120 100 102.22 5.41
1 h r5 m in 105 95 110 120 120 90 83 100 108 103.44 4.50
1 hr 10 min 190 95 100 138 115 90 80 90 95 110.33 12.16
1 hr 15 min 200 78 100 120 108 90 80 95 108.88 14.88
1 hr 20 min 180 78 100 120 119 90 85 95 108.38 12.32
1 hr 25 min 180 80 100 120 115 92 92 98 109.63 11.79
1 hr 30 min 195 80 100 130 115 100 98 116.86 15.42
1 hr 35 min 200 79 100 118 115 90 98 114.29 16.39
1 hr 40 min 78 102 120 115 90 93 99.67 21.16
1 hr 45 min 78 107 118 80 98 96.20 8.62
1 hr 50 min 80 107 115 100 98 100.00 6.51
1 hr 55 min 78 110 120 100 90 99.60 8.23
2 hrs 76 110 120 100 101.50 10.89
2 hr 5 min 78 112 120 88 99.50 11.41
2 hr 10 min 78 112 120 95 101.25 10.78
2 hrs 15 min 78 110 120 98 101.50 10.43
2 hr 20 min 80 110 120 90 100.00 10.54
2 hrs 25 min 80 110 120 100 102.50 9.86
2 hr 30 min 79 110 125 100 103:50 11.14
2 hrs 35 min 70 100 130 100 100.00 14.14
2 hr 40 min 90 89 130 95 101.00 11.26
2 hrs 45 min 120 97 132 100 11Z25 9.62
2 hr 50 min 120 97 140 105 115.50 10.92
2 hrs 55 min 93 100 96.50 4.95
3 hrs 100 100.00
3 hrs 5 min 80 80.00
3 hr 10 min 90 90.00
3 hrs 15 min 80 80.00
3 hr 20 min 90 90.00
3 hrs 25 min 95 95.00
3 hr 30 min 110 110.00
ABBREVIATIONS
Pre = Prior to induction of anaesthesia
Mean = Mean of the pulse readings
SEM = Standard error of means
min =  minute
pulse =  beats/minute
hr = hour
Table A4 : Pulse readings +/-SEM, in beats/minute, of the individual dogs in group B, 
taken every 5 minutes throughout anaesthesia.
Dogs trial numbers 11-20 (group B), received flunixin meglumine, 1.1 mg/kg, i.v., 
immediately after anaesthesia had terminated.
Pulse readings in beats/minute
Trial No- 11 12 13 14 15 16 17 18 Mi VO O Mean SEM
Time
Pre 100 100 102 112 88 200 120 110 80 100 111.20 11.08
0 min 120 131 170 140 136 120 100 131.00 8.87
5m in 120 130 120 105 82 166 135 100 113 131 120.00 7.60
10 min 112 110 100 90 78 187 120 96 97 93 108.30 10.05
15 min 100 120 100 85 70 147 120 90 101 107 104.00 7.14
20 min 112 120 100 89 78 131 117 117 89 108 106.10 5.56
25 min 108 120 100 89 74 150 119 110 120 108 109.80 6.78
30 min 95 125 110 89 71 163 117 108 101 107 108.60 8.12
35 min 95 120 80 95 74 156 117 111 108 102 105.80 7.70
40 min 100 120 90 95 78 129 119 119 110 92 105.20 5.52
45 min 100 120 90 100 78 133 117 98 104 100 104.00 5.24
50 nain 98 110 100 100 89 133 116 101 101 101 104.90 4.06
55 min 98 120 100 102 70 141 116 100 102 100 104.90 6.09
1 hr 105 110 90 98 77 153 119 97 104 100 105.30 6.73
I hr 5 min 105 120 100 90 74 159 109 107 105 111 108.00 7.30
1 hr 10 min 100 120 100 82 84 163 111 107 104 113 108.40 7.53
I hr 15 min 120 120 98 87 83 159 120 104 104 107 110.20 7.19
1 hr 20 min 95 120 98 92 129 156 130 104 102 115 114.10 6.69
1 hr 25 min 100 120 89 102 163 135 100 100 122 114.56 8.19
1 hr 30 min 120 125 84 96 156 120 97 104 120 113.56 7.50
1 hr 35 min 100 115 90 90 156 98 104 129 110.25 8.55
1 hr 40 min 110 120 90 89 156 97 89 153 113.00 19.14
1 hr 45 min 120 110 84 89 159 96 72 144 109.25 11.44
1 hr 50 min 98 120 80 108 159 94 115 150 115.50 10.29
1 hr 55 min 100 130 92 106 153 94 84 159 114.75 10.92
2 hrs 100 120 92 98 153 97 71 153 110.50 11.12
2 hr 5 min 100 130 100 99 150 98 73 163 114.13 11.52
2 hr 10 min 100 120 90 99 153 110 84 166 115.25 11.21
2 hrs 15 min 95 120 90 98 125 127 170 117.86 22.58
2 hr 20 min 95 120 80 102 136 111 170 116.29 12.12
2 hrs 25 min 100 130 72 98 138 110 170 116.86 13.06
2 hr 30 min 100 140 60 98 156 178 122.00 19.51
2 hrs 35 min 100 130 98 170 182 136.00 19.44
2 hr 40 min 98 125 98 182 125.75 22.86
2 hrs 45 min 100 130 98 182 127.50 22.62
2 hr 50 min 100 99 174 124.33 30.42
2 hrs 55 min 98 182 140.00 59.40
3 hrs 92 187 139.50 67.18
3 hrs 5 min 92 197 144.50 74.25
3 hr 10 min 89 202 145.50 79.90
3 hrs 15 min 89 89.00
3 hr 20 min 80 80.00
3 hrs 25 min 82 82.00
3 hr 30 min
ABBREVIATIONS
Pre =  Prior to induction of anaesthesia
Mean =  Mean of the pulse readings
SEM = Standard error of means
min = minute
pulse =  beats/minute
h r= hour
Table A5 : Respiratory rates +/-SEM, in breaths/minute, of the individual dogs in group A, 
taken every 5 minutes throughout anaesthesia.
Dogs trial numbers 1-10 (group A), received flunixin meglumine, 1.1 mg/kg, i.v., during 
anaesthesia, prior to the start of surgery.
Respiratory rates in breaths/minute
T rial No- 1 2 3 4 . 5 " 6 7 8 9| 10 M ean SEM
Time
Pre 64 28 24 32 28 35.20 8.17
0 min 6 15 20 16 36 30 50 24.71 6.10
5 min 6 10 25 20 30 12 12 28 16 32 19.10 3.07
10 m in 6 25 25 10 28 12 8 20 16 12 16.20 2.61
15m in 10 15 20 10 15 16 16 16 24 40 18.20 2.90
20 min 10 20 20 15 15 16 16 20 8 20 16.00 1.43
25 min 34 15 25 10 25 24 12 20 12 16 19.30 2.55
30 mirt 6 20 20 10 30 24 12 20 10 16 16.80 2.46
35 min 6 20 20 10 30 24 8 20 12 15 16.50 2.54
40 min 20 25 25 10 20 24 12 24 12 20 19.20 1.94
45 min 25 20 20 15 20 24 12 20 12 16 18.40 1.51
50 m in 20 20 25 15 28 24 16 20 24 24 21.60 1.37
55 min 10 25 25 20 25 24 12 24 12 19.67 2.28
1 hr 44 20 25 22 25 24 12 24 30 25.11 3.04
1 hr 5 min 50 20 27 22 20 24 12 28 35 26.44 3.85
1 hr 10 min 30 20 25 12 20 22 12 20 40 22.33 3.08
1 hr 15 min 20 35 25 12 20 20 12 30 30 22.67 2.83
1 hr 20 min 20 30 25 12 25 12 20 40 23.00 3.52
1 hr 25 min 29 25 15 25 12 22 40 24.00 3.77
1 hr 30 min 30 25 16 25 10 50 26.00 6.16
1 hr 35 min 35 30 12 25 10 40 25.33 5.45
1 hr 40 min 30 25 12 28 20 40 25.83 4.24
1 hr 45 min 30 30 29 20 40 29.80 3.54
1 hr 50 min 28 35 30 18 35 29.20 3.49
1 hr 55 min 30 35 25 18 40 29.60 4.28
2 hrs 30 30 29 15 26.00 4.24
2 hr 5 min 30 30 25 15 25.00 4.08
2 hr 10 min 30 30 25 15 25.00 4.08
2 hrs 15 min 28 30 28 12 24.50 4.84
2 hr 20 min 28 30 24 16 24 50 3.57
2 hrs 25 min 24 30 25 12 2Z75 4.41
2 hr 30 min 30 35 25 10 25.00 6.24
2 hrs 35 min 60 30 28 20 34; 50 10.13
2 hr 40 min 40 28 20 15 25.75 6.30
2 hrs 45 min 20 20 25 18 20.75 1.72
2 hr 50 min 40 20 25 18 25.75 5.74
2 hrs 55 min 20
3 hrs 20
3 hrs 5 min 20
3 hr 10 min 20
3 hrs 15 thin 20
3 hr 20 min 20
3 hrs 25 min 20
3 hr 30 min 20
ABBREVIATIONS
Pre = Prior to induction of anaesthesia min = minute
Mean =  Mean of the respiratoiy rate readings respiratoiy rate = breaths/minute
SEM = Standard error of means hr = hour
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Table A6 : Respiratory rates +/-SEM, in breaths/minute, of the individual dogs in group B, 
taken every 5 minutes throughout anaesthesia.
Dogs trial numbers 11-20 (group B), received flunixin meglumine, 1.1 mg/kg, i.v., immediately 
after anaesthesia had terminated.
Respiratory rates in breaths/minute
T rial No- 11 12 13 14 15 16 17 18 19 20 Mean SEM
Time
Pre 20 64 36 20 35.00 11.98
0 min 25 26 52 36 12 36 31.17 6.04
5 min 12 20 12 24 8 52 24 20 6 19.78 4.88
lO m in 16 25 12 18 8 30 20 16 12 26 18.30 2.33
15 min 16 30 20 18 12 16 20 16 16 32 19.60 2.15
20 min 12 35 12 16 16 15 16 20 20 32 19.40 2.64
25 min 16 50 12 18 20 20 12 12 28 18.80 4.39
30 min 16 50 20 20 24 24 16 28 24 24.67 3.64
35 min 20 43 16 20 20 32 22 24 28 25.00 2.93
40 min 20 35 16 30 21 20 22 24 22 23.33 2.04
45 min 20 35 16 60 28 26 20 20 12 26.33 5.07
50 min 20 25 18 60 20 20 16 32 20 25.67 4.84
55 min 16 30 16 64 22 20 24 28 24 27.11 5.17
1 hr 24 30 16 26 26 20 24 32 20 24.22 1.78
1 hr 5 min 16 30 12 20 20 16 36 28 28 22.89 2.81
1 hr lOm in 20 37 12 26 26 36 28 24 28 26.33 2.69
1 hr 15 min 16 35 20 60 20 30 24 28 28 29.00 4.60
1 hr 20 min 20 32 12 62 42 22 24 28 30.25 7.30
1 hr 25 min 22 40 16 50 36 24 24 28 30.00 4.22
1 hr 30 min 30 40 16 32 36 22 76 28 35.00 6.88
1 hr 35 min 20 30 16 28 30 22 40 28 26.75 2.80
1 hr 40 min 20 35 16 30 24 20 80 16 30.13 8.02
1 hr 45 min 16 30 14 28 32 20 20 22.86 2.90
1 hr 50 min 20 44 14 24 32 20 24 25.43 4.02
1 hr 55 min 20 45 16 20 22 16 24 23.29 4.09
2 hrs 20 45 15 16 22 16 24 22.57 4.27
2 hr 5 min 24 40 12 20 12 28 22.67 4.76
2 hr 10 min 20 30 12 16 30 21.60 4.09
2 hrs 15 min 24 30 12 24 30 24.00 3.67
2 hr 20 min 24 30 12 20 32 23.60 4.02
2 hrs 25 min 24 35 12 16 42 25.80 6.31
2 hr 30 min 24 32 12 18 40 25.20 5.55
2 hrs 35 min 20 32 18 34 26.00 4.71
2 hr 40 min 20 30 18 36 26.00 4.90
2 hrs 45 min 20 30 20 42 28.00 6.04
2 hr 50 min 20 20 50 30.00 12.25
2 hrs 55 min 20
3 hrs 20
3 hrs 5 min 20
3 hr 10 min 35
3 hrs 15 min 25
3 hr 20 min 25
3 hrs 25 min 25
3 hr 30 min
ABBREVIATIONS
Pre = Prior to induction of anaesthesia
Mean = Mean of the respiratory rate readings
SEM = Standard error of means
min =  minute
respiratory rate = breaths/minute
h r= hour
1 1 0
Table A7 : End tidal carbon dioxide (ETC02) readings +/-SEM in mm Hg, of dogs trial 
numbers 1, 2, 3, 8, and 9 in group A, taken every 5 minutes from the commencement of 
surgery, till termination of anaesthesia.
Dogs in group A, received flunixin meglumine, 1.1 mg/kg, i.v., during anaesthesia, prior 
to the start of surgery.
ETCQ2 readings in mm Hg
Trial No- 1 2 3 8 9 Mean SEM
Time
15 mm 37
20 mm 35 35 35.00 0.00
25 min 32 35 33.50 2.12
30 min 37 35 36.00 1.41
35 min 37 35 36.00 1.41
40 min 37 35 36.00 1.41
45 min 34 35 34.50 0.71
50 min 32 35 33.50 2.12
55 min 32 35 33.50 2.12
1 hr 35
1 hr 5 min
1 hr 10 min 28
1 hr 15 min 28
1 hr 20 min 28 38 33.00 7.07
1 hr 25 min 32 38 35.00 4.24
1 hr 30 min 34 31 38 34.50 2.48
1 hr 35 min 34 30 40 34.60 3.56
1 hr 40 min 32 33 40 35.00 3.08
1 hr 45 min 31 29 40 33.30 4.14
1 hr 50 min 32 33 40 35.00 3.08
1 hr 55 min 32 29 36 32.33 2.48
2 hrs 32 32 36 33.30 1.63
2 hr 5 min 32 34 25 30.30 2.01
2 hr 10 min 32 34 33.00 1.41
2 hrs 15 min 32 33 32.50 0.71
2 hr 20 min 30 33 31.50 2.12
2 hrs 25 min 33
2 hr 30 min 33
2 hrs 35 min 30
2 hr 40 min 31
2 hrs 45 min 30
2 hr 50 min
2 hrs 55 min
3 hrs
3 hrs 5 min
ABBREVIATIONS
Pre = Prior to induction of anaesthesia
Mean = Mean end tidal carbon dioxide readings
SEM = Standard error of means
min = minute
ETC02 = millimeters of mercury (mm Hg)
hr = hour
1 1 1
Table A8 : End tidal carbon dioxide (ETC02) readings +/-SEM in mm Hg, of dogs trial 
numbers 11, 12, 14, 16, 17, 18, 19 and 20 in group B, taken every 5 minutes from 
the commencement of surgery, till termination of anaesthesia.
Dogs in group B, received flunixin meglumine, 1.1 mg/kg, i.v., immediately after 
anaesthesia had terminated.
ETCQ2 readings in mm Hg
T rial No- 11 12 14 16 17 18 19 20 Mean SEM
Tim e
5 min 38 38.00
10 min 38 38.00
15 min 37 37.00
20 min 36 40 38.00 2.83
25 min 36 48 34 39.33 5.35
30 min 36 40 34 36.67 2.16
35 min 37 34 34 35.00 1.22
40 min 36 39 35 36.67 1.47
45 min 42 35 33 45 38.75 3.28
50 min 44 35 38 32 42 38.20 2.46
55 min 38 35 38 33 37 36.20 1.08
1 hr 31 32 38 33 37 34.20 1.56
1 hr 5 min 38 40 32 38 31 36 35.83 1.61
1 hr 10 min 38 34 28 36 32 35 33.83 1.56
1 hr 15 min 38 31 40 40 36 37.00 1.87
1 hr 20 min 38 35 40 36 35 36.80 1.08
1 hr 25 min 32 32 36 38 35 34.60 1.30
1 hr 30 min 32 26 40 39 37 34.80 2.90
1 hr 35 min 38 32 40 23 35 33.60 3.33
1 hr 40 min 38 40 35 40 18 35 34.33 3.72
1 hr 45 min 38 40 36 32 38 34 36.33 1.32
1 hr 50 min 38 40 42 36 36 36 38.00 1.13
1 hr 55 min 40 40 45 34 35 36 38.33 1.85
2 hrs 40 42 44 35 34 36 38.50 1.83
2 hr 5 min 40 45 41 36 40.50 2.13
2 hr 10 min 40 42 43 36 40.25 1.79
2 hrs 15 min 40 42 46 34 40.50 2.89
2 hr 20 min 40 42 46 32 40.00 3.40
2 hrs 25 min 40 42 45 34 40.25 2.68
2 hr 30 min 40 47 34 40.33 4.60
2 hrs 35 min 39 48 38 41.67 3.89
2 hr 40 min 39 47 32 39.33 5.31
2 hrs 45 min 35 48 32 38.33 6.01
2 hr 50 min 35.00 15.56
2 hrs 55 min 48 20 32.50 17.68
3 hrs
3 hrs 5 min 39
ABBREVIATIONS
Pre = Prior to induction of anaesthesia
Mean = Mean end tidal carbon dioxide readings
SEM = Standard error of means
min = minute
ETC02 = millimeters of mercury (mm Hg)
hr = hour
Table A8 : End tidal carbon dioxide (ETC02) readings +/-SEM in mm Hg, of dogs tnal 
numbers 11, 12, 14, 16, 17, 18, 19 and 20 in group B, taken every 5 minutes from 
the commencement of surgery, till termination of anaesthesia.
Dogs in group B, received flunixin meglumine, 1.1 mg/kg, i.v., immediately after 
anaesthesia had terminated.
ETCQ2 readings in mm Hg
Trial No- 11 12 14 16 17 18 19 20 Mean SEM
Time
5 min 38 38.00
10 min 38 38.00
15 nuin 37 37.00
20 min 36 40 38.00 2.83
25 min 36 48 34 39.33 5.35
30 min 36 40 34 36.67 2.16
35 min 37 34 34 35.00 1.22
40 min 36 39 35 36.67 1.47
45 min 42 35 33 45 38.75 3.28
50 min 44 35 38 32 42 38.20 2.46
55 min 38 35 38 33 37 36.20 1.08
1 hr 31 32 38 33 37 34.20 1.56
1 hr 5 min 38 40 32 38 31 36 35.83 1.61
1 hr 10 min 38 34 28 36 32 35 33.83 1.56
1 hr 15 min 38 31 40 40 36 37.00 1.87
1 hr 20 mm 38 35 40 36 35 36.80 1.08
1 hr 25 min 32 32 36 38 35 34.60 1.30
1 hr 30 min 32 26 40 39 37 34.80 2.90
1 hr 35 min 38 32 40 23 35 33.60 3.33
1 hr 40 min 38 40 35 40 18 35 34.33 3.72
1 hr 45 min 38 40 36 32 38 34 36.33 1.32
1 hr 50 min 38 40 42 36 36 36 38.00 1.13
1 hr 55 min 40 40 45 34 35 36 38.33 1.85
2 hrs 40 42 44 35 34 36 38.50 1.83
2 hr 5 mm 40 45 41 36 40.50 2.13
2 hr 10 min 40 42 43 36 40.25 1.79
2 hrs 15 min 40 42 46 34 40.50 2.89
2 hr 20 mm 40 42 46 32 40.00 3.40
2 hrs 25 min 40 42 45 34 40.25 2.68
2 hr 30 min 40 47 34 40.33 4.60
2 hrs 35 min 39 48 38 41.67 3.89
2 hr 40 mm 39 47 32 39.33 5.31
2 hrs 45 min 35 48 32 38.33 6.01
2 hr 50 min 35.00 15.56
2 hrs 55 min 48 20 32.50 17.68
3 hrs
3 hrs 5 min 39
ABBREVIATIONS
Pre = Prior to induction of anaesthesia
Mean = Mean end tidal carbon dioxide readings
SEM =  Standard error o f means
min = minute
ETC02 =  millimeters of mercury (mm Hg)
lir = hour
1 1 2
Fig. A 1 : Individual mean blood pressure (mmHg) readings o f dogs in Group A (No 1-5)
versus time. Group A dogs received flunixin, l.lm g/kg, i.v., during anaesthesia,
prior to the start o f surgery.
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Fig. A2: Individual mean blood pressure (mmHg) readings o f dogs in Group A (No 6-10)
versus time. Group A dogs received flunixin, l.lm g/kg, i.v., during anaesthesia,
prior to the start o f surgery.
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Fig. A3: Individual mean blood pressure (mmHg) readings of dogs in Group B (No 11-15)
versus time. Group B (No 11-20) versus time. Group B dogs received flunixin,
l.lmg/kg, i.v., immediately after surgery and anaesthesia had been terminated.
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Fig. A4: Individual mean blood pressure (mmHg) readings o f  dogs in Group B (No 16-20)
versus time. Group B (No 11-20) versus time. Group B dogs received flunixin,
1.1 mg/kg, i.v., immediately after surgery and anaesthesia had been terminated.
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Fig. A5: Individual pulse readings (beats/min) of dogs in Group A (No 1-5) versus time.
Group A dogs received flunixin, 1.1 mg/kg, i.v., during anaesthesia, prior to the
start of surgery.
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Fig. A6: Individual pulse readings (beats/min) of dogs in Group A (No 6-10) versus time.
Group A dogs received flunixin, 1.1 mg/kg, i.v., during anaesthesia, prior to the
start of surgery.
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Fig. A7: Individual pulse readings (beats/min) of dogs in Group B (No 11-15) versus time.
Group B dogs received flunixin, 1.1 mg/kg, i.v., immediately after surgery and
anaesthesia had been terminated.
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Fig. A8: Individual pulse readings (beats/min) of dogs in Group B (No 16-20) versus time. 
Group B dogs received flunixin, 1.1 mg/kg, i.v., immediately after surgery and 
anaesthesia had been terminated.
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Fig. A9: Individual respiratory readings (breaths/min) of dogs in Group A (No 1-5) versus
time. Group A dogs received flunixin, 1.1 mg/kg, i.v., during anaesthesia, prior
to the start of surgery.
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Fig. A10: Individual respiratory readings (breaths/min) of dogs in Group A (No 6-10) versus
time. Group A dogs received flunixin, l.lmg/kg, i.v., during anaesthesia, prior to
the start of surgery.
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Fig. A11: Individual respiratory readings (breaths/min) of dogs in Group B (No 11-15)
versus time. Group B dogs received flunixin, l.lmg/kg, i.v., immediately after
surgery and anaesthesia had been terminated.
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Fig. A12: Individual respiratory readings (breaths/min) of dogs in Group B (No 16-20)
versus time. Group B dogs received flunixin, l.lmg/kg, i.v., immediately after
surgery and anaesthesia had been terminated.
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Fig. A 1 3: Individual End tidal carbon dioxide (ETC02) readings (mmHg) o f dogs
No 1, 2, 3, 8 and 9 in Group A versus time. Group A dogs received flunixin, 
1. lmg/kg, i.v., during anaesthesia, prior to the start o f surgery.
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Fig. A 14: Individual End tidal carbon dioxide (ETC02) readings (mmHg) of dogs No 11,
12, 14, 16, 17, 18, 19 and 20 in Group B versus time. Group B dogs received flunixin,
1.1 mg/kg, i.v., immediately after surgery and anaesthesia had been terminated.
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APPENDIX B
TABLES
TABLE B 1 - Normal canine biochemistry values.
TABLE B2 - Biochemical profile o f a group o f 10 control dogs, who underwent routine 
anaesthesia and surgery, but were not given flunixin as an analgesic.
Table B 2.1 - Biochemical profile prior to induction o f anaesthesia.
Table B2.2 - Biochemical profile 12 hours after termination o f anaesthesia.
Table B2.3 - Biochemical profile 30 hours after termination o f anaesthesia.
TABLE B3 - Biochemical profiles o f dogs in group A (Trial No: 1-10), who received 
flunixin meglumine, 1.1 mg/kg i.v., prior to the start o f surgery.
Table B 3.1 - Biochemical profile prior to induction o f anaesthesia.
Table B3.2 - Biochemical profile 12 hours after flunixin administration.
Table B3.3 - Biochemical profile 30 hours after flunixin administration.
Table B3.4- Biochemical profile o f dog numbered 8, taken 60 days after flunixin 
administration and dog number 10, taken 15, 60 and 150 days after flunixin 
administration.
TABLE B4 - Biochemical profiles o f dogs in group B (Trial No: 11-20), who received 
flunixin meglumine, 1.1 mg/kg i.v., immediately after surgery and anaesthesia had 
terminated.
Table B 4.1 - Biochemical profile prior to induction o f anaesthesia.
Table B4.2 - Biochemical profile 12 hours after flunixin administration.
Table B4.3 - Biochemical profile 30 hours after flunixin administration.
Table B4.4 - Biochemical profile o f dog numbered 15; 15, 30 and 60 days after 
flunixin administration.
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Table B l: Normal canine biochemistry values.
(Glasgow University Veterinary Hospital, Biochemistry Department)
TEST NORMAL 
CANINE VALUES
S.L UNITS
UREA 2 - 8 millimol/litre (mmol/1)
CREATININE 44 - 135 micromol/litre (umol/1)
PHOSPHATE 1 -3 millimol/litre (mmol/1)
TOTAL PROTEIN 5 0 -7 0 grams/litre (g/1)
ALBUMIN 3 0 -4 0 grams/litre (g/1)
GLOBULIN 2 0 -3 0 grams/litre (g/1)
SODIUM 135 - 160 millimol/litre (mmol/1)
POTASSIUM 3 - 6 millimol/litre (mmol/1)
CHLORIDE 9 5 - 115 millimol/litre (mmol/1)
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Table B2: Kidney biochemical profile, o f a group o f 10 control dogs (C l - CIO), who 
underwent routine anaesthesia (ACP- 0.05 mg/kg i.m, Thio - 10 mg/kg i.v., halothane in 
N 2 O/O2 ) and surgery. Blood was taken for analysis prior to induction o f anaesthesia, 12 
and 30 hours after commencement o f anaesthesia.
B 2.1. BIOCHEMICAL PROFILE:- Prior to induction o f anaesthesia
Dog No -> C l C2 C3 C4 C5 C6 C l C8 C9 CIO
Urea (mmol/1) 2.9 4.4 5.4 5.9 7.8 6.1 4 3.6 4.8 7.7
Creatinine (umol/1) 106 70 118 95 85 127 90 92 80 75
Phosphate (mmol/1) 1.41 1.17 1.02 2.08 1.64 1.49 1 1.4 1.57 1.85
Total protein (g/1) 56 66 63 68 68 60 64 66 60 56
Albumin (g/1) 32 33 33 40 37 26 29 32 33 31
Globulin (g/1) 24 33 29 28 31 34 35 34 27 25
Sodium (mmol/1) 151 148 151 150 149 148 146 149 148 149
Potassium (mmol/1) 4 4.3 3.7 3.4 3.4 4 3.9 3.8 4.4 4.3
Chloride (mmol/1) 108 109 114 118 118 107 108 116 109 110
B2.2 BIOCHEMICAL PROFILE:- 12 hours after termination o f anaesthesia
Dog No -» C l C2 C3 C4 C5 C6 C l C8 C9 CIO
Urea (mmol/1) 3.6 5.3 4.6 6 6.2 6.5 2.9 2.7 3.6 4.1
Creatinine (umol/1) 88 84 78 96 115 109 84 83 66 93
Phosphate (mmol/1) 1.39 1.57 2.55 1.31 1.48 1.24 1.02 1.37 1.39 1.27
Total protein (g/1) 63 66 55 62 62 52 60 61 60 60
Albumin (g/1) 31 29 33 37 35 23 27 32 32 33
Globulin (g/1) 32 37 22 25 27 29 33 29 28 27
Sodium (mmol/1) 149 149 150 148 149 146 136 149 143 148
Potassium (mmol/1) 3.7 5.6 5.3 3.6 4.2 4.2 4.5 4.4 4.7 4.3
Chloride (mmol/1) 111 111 109 115 114 109 103 113 105 110
B2. 3 BIOCHEMICAL PROFILE:- 30 hours after termination o f anaesthesia
Dog No -> C l C2 C3 C4 C5 C6 C7 C8 C9 CIO
Urea (mmol/1) 2.7 5.4 5.9 6.5 7.6 4.7 4.3 4.9 3.5 7.2
Creatinine (umol/1) 89 87 81 110 99 109 110 82 70 107
Phosphate (mmol/1) 1.46 1.26 2.72 1.83 1.64 1.7 1.12 1.43 1.01 1.16
Total protein (g/1) 59 72 53 65 66 52 64 64 67 59
Albumin (g/1) 27 30 33 37 38 24 28 34 34 31
Globulin (g/1) 32 42 20 28 28 28 36 30 33 28
Sodium (mmol/1) 147 144 145 146 146 148 144 147 148 143
Potassium (mmol/1) 4.2 5.4 5.6 3.8 4.5 4.8 4.3 4.9 4.2 3.9
Chloride (mmol/1) 106 103 105 114 121 108 110 107 106 108
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Table B3: Kidney biochemical profiles o f dogs in group A (1 - 10), who received flunixin 
meglumine, 1.1 mg/kg i.v. during anaesthesia, prior to the start o f surgery. Blood was 
taken for analysis prior to the administration o f flunixin, and 12 and 30 hours after its 
administration.
B3.1. BIOCHEMICAL PROFILE:- hior to flunixin administration.
Dog No -» 1 2 3 4 5 6 7 8 9 10
Urea (mmol/1) NS 4.8 NS 2.8 4.3 6.3 3.5 6.3 4.6 3.6
Creatinine (umol/1) NS 117 NS 68 101 74 79 85 93 127
Phosphate (mmol/l) NS 1.23 NS 1.41 2.43 1.24 1.93 1.45 0.91 1.29
Total protein (g/1) NS 53 NS 61 50 64 56 56 61 NS
Albumin (g/1) NS 34 NS 24 28 27 33 26 29 NS
Globulin (g/1) NS 19 NS 37 22 37 23 30 32 NS
Sodium (mmol/l) NS 146 NS 145 147 149 146 148 148 148
Potassium (mmol/l) NS 4.2 NS 3.8 5 4.6 4.7 4.4 4.6 4.1
Chloride (mmol/l) NS 115 NS 114 110 118 116 113 111 119
B3.2 BIOCHEMICAL PROlTLE:- 12 hours after flunixin ac ministration.
Dog No -» 1 2 3 4 5 6 7 8 9 10
Urea (mmol/l) 8.4 10.2 NS 7.8 5.9 5.4 6.4 8.7 6.2 6.2
Creatinine (umol/1) 113 192 NS 81 112 75 98 112 121 125
Phosphate (mmol/l) 1.58 1.51 NS 1.15 2.21 1.29 2.32 1.24 1.67 1.63
Total protein (g/1) 62 64 NS 58 52 66 52 57 61 47
Albumin (g/1) 29 36 NS 22 30 27 21 27 29 24
Globulin (g/1) 33 28 NS 36 22 39 31 30 32 23
Sodium (mmol/l) 150 145 NS 140 147 147 147 146 150 150
Potassium (mmol/l) 4 4.1 NS 4.1 4.8 5 5.1 4.8 4.7 5.2
Chloride (mmol/l) 115 109 NS 111 112 114 116 114 109 119
B3. 3 BIOCHEMICAL PROFILE:- 30 hours after flunixin administration.
Dog No —> 1 2 3 4 5 6 7 8 9 10
Urea (mmol/l) 6.2 NS NS 5.6 5.5 5.7 5.1 8.1 6.6 6.8
Creatinine (umol/1) 101 NS NS 78 100 82 98 112 119 100
Phosphate (mmol/l) 1.07 NS NS 1.58 2.09 1.26 2.11 1.36 1.38 1.7
Total protein (g/1) 50 NS NS 62 44 62 53 62 49 NS
Albumin (g/1) 32 NS NS 24 25 25 32 29 23 NS
Globulin (g/1) 18 NS NS 38 19 37 21 33 26 NS
Sodium (mmol/l) 151 NS NS 142 149 145 149 146 151 149
Potassium (mmol/l) 4 NS NS 4.1 4.8 4.7 4.4 4.7 3.4 4.1
Chloride (mmol/l) 114 NS NS 106 115 117 119 117 NS 122
NS = Not sampled
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B3. 4 BIOCHEMICAL PROFILES: -o f dog 8 taken 60 days after flunixin administration.
-o f dog 10 taken 15, 60 and 150 days after flunixin 
administration.
Parameters Dog 8 
(60 days)
Dog 10 
(15 days)
Dog 10 
(60 days)
Dog 10 
(150 days)
Urea (mmol/l) 4.1 6.6 7.9 7.4
Creatinine (umol/1) 88 147 100 113
Phosphate (mmol/l) 1.06 1.21 1.39 1.2
Total protein (g/1) 64 57 50 56
Albumin (g/1) 27 30 34 34
Globulin (g/1) 37 27 16 22
Sodium (mmol/l) 142 148 151 146
Potassium (mmol/l) 4.4 3.8 3.9 4.5
Chloride (mmol/l) 110 118 112 116
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Table B4: Kidney biochemical profiles o f trial dogs in group B (Trial No : 11 - 20), who 
received flunixin meglumine, 1.1 mg/kg i.v. immediately after surgery and anaesthesia had 
been terminated. Blood was taken for analysis prior to the administration o f flunixin, and 
12 and 30 hours after its administration.
B4. 1. BIOCHEMICAL PROFILE:- Prior to flunixin administration
Dog No —► 11 12 13 14 15 16 17 18 19 20
Urea (mmol/l) 4.4 4.7 2.9 5.4 4.2 4.7 3.8 4 4.5 4.3
Creatinine (umol/1) 72 69 77 91 83 119 73 71 79 115
Phosphate (mmol/l) 1.98 1.45 1.06 2 1.6 1.62 1.69 1.47 2.19 1.21
Total protein (g/1) 49 50 54 57 48 53 67 50 55 51
Albumin (g/1) 26 26 26 28 23 28 28 27 26 25
Globulin (g/1) 23 24 28 29 25 25 39 23 29 26
Sodium (mmol/l) 147 147 149 146 147 147 145 150 149 146
Potassium (mmol/l) 4.5 4.7 4.5 4.8 4.7 4 4.5 4.2 4.3 4.4.
Chloride (mmol/l) 112 115 115 115 113 111 110 112 111 115
B4. 2 BIOCHEMICAL PROFILE:- 2 hours after flunixin administration
Dog No -> 11 12 13 14 15 16 17 18 19 20
Urea (mmol/l) 5.6 5.1 5.2 5.6 4.4 5.1 3.9 5.6 7.4 5.5
Creatinine (umol/1) 74 69 87 103 78 113 60 79 88 127
Phosphate (mmol/l) 1.81 2.05 1.4 1.6 1.26 1.44 1.24 1.26 1.27 1.42
Total protein (g/1) 52 55 52 56 48 NS1 63 51 53 43
Albumin (g/1) 29 28 25 29 24 NS 27 27 26 23
Globulin (g/1) 23 27 27 27 24 NS 36 24 27 20
Sodium (mmol/l) 148 147 144 148 149 146 148 150 151 139
Potassium (mmol/l) 5.4 4.7 4.4 4.2 4.6 5.2 4.8 5 5 4.6
Chloride (mmol/l) 113 111 110 119 116 113 114 113 113 111
B4. 3 BIOCHEMICAL PROFILE:- 30 hours after flunixin administration
Dog No -> 11 12 13 14 15 16 17 18 19 20
Urea (mmol/l) 2 5.9 4.3 5 2.2 5.1 3.2 4.7 5.1 10.1
Creatinine (umol/1) 68 74 88 114 66 110 64 85 90 134
Phosphate (mmol/l) 1.52 2.12 1.54 1.5 1.33 1.74 1.51 1.24 1.46 1.46
Total protein (g/1) 48 54 56 60 50 61 67 54 58 52
Albumin (g/1) 28 27 29 30 24 32 31 30 28 27
Globulin (g/1) 20 27 27 30 26 29 40 24 30 25
Sodium (mmol/l) 148 145 148 147 147 147 148 149 148 144
Potassium (mmol/l) 4.7 5.6 4.5 4.6 4.8 4.8 4.6 4.5 4.5 4.3
Chloride (mmol/l) 109 106 NS 4 116 113 111 106 107 116
1 NS = Not sampled 132
B4. 4 BIOCHEMICAL PROFILE o f dog No 15 taken 15, 30 and 60 days after flunixin 
administration.
Parameters 15 days 30 days 60 days
Urea (mmol/l) 3.7 5.2 4.2
Creatinine (umol/1) 97 84 61
Phosphate (mmol/l) 1.08 1.64 1.75
Total protein (g/1) 54 55 55
Albumin (g/1) 28 25 26
Globulin (g/1) 26 30 29
Sodium (mmol/l) 148 149 148
Potassium (mmol/l) 4.1 4.6 5.4
Chloride (mmol/l) 112 117 112
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APPENDIX C
TABLES
TABLE C l - Intra-assay coefficient o f variation for flunixin analysis.
TABLE C2 - Inter-assay coefficient o f variation for flunixin analysis.
TABLE C3 - Plasma concentrations o f flunixin (pg/ml), together with mean 
concentrations ± SEM48, measured using HPLC, following intravenous administration o f  
a single dose o f 1.1 mg/kg flunixin, to dogs in group A (Trial numbers 1 - 10).
TABLE C4 - Plasma concentrations o f flunixin (pg/ml) together with mean concentrations
+ SEM, measured using HPLC, following intravenous administration o f a single dose o f
1.1 mg/kg flunixin, to dogs in group B (Trial numbers 11 - 20).
48SEM = Standard error of means
134
Table C l:  Intra-assay coefficient of variation of the HPLC technique used for flunixin
analysis, in this study
This table gives the coefficient of variation of replicated plasma samples, to which known concentrations 
of the drug flunixin has been added (spike samples), and analysed in a single assay. In this assay, 0.25 mis 
of canine plasma was used initially for the extraction procedure (plasma volume), but only 0.15 mis 
of the extracted mixture was analysed by the HPLC machine (residual volume). The % recovery of the 
drug by this method was 66.66%.
S.No Cone of 
sample
Peak height 
of sample
Peak height 
of standard
Std
cone
% recovery 
offlunixin
Mean % 
recovery
Sample 
std. dev
Sample 
std. error
Coefficient of 
variation (%)
51
52
53
54
0.25
0.25
0.25
0.25
15.25
12.75
14.00
14.00
64.30
65.50
65.50
68.50
1.00
1.00
1.00
1.00
85.46
70.08
76.95
73.58
76.5 6.59 3.29 8.61
55
56
57
58
1.00
1.00
1.00
1.00
61.50
66.00
58.25
67.00
68.50 
68.00 
68.00
68.50
1.00
1.00
1.00
1.00
80.81
87.36
77.10
90.01
83.8 5.92 2.96 7.06
S9
510
511
512
2.00
2.00
2.00
2.00
44.50
47.50 
51.25
48.50
54.50
53.80
53.80 
53.30
2.00
2.00
2.00
2.00
73.49
79.54
85.82
81.98
80.2 5.17 2.59 6.45
513
514
515
516
5.00
5.00
5.00
5.00
72.75
64.50
54.50 
53.00
68.50
68.50
63.00
63.00
5.00
5.00
5.00
5.00
95.59
84.75
77.86
75.72
83.5 8.95 4.47 10.72
517
518
519
520
10.00
10.00
10.00
10.00
59.75
57.50 
54.25
53.50
61.30
61.30
58.80
58.80
10.00
10.00
10.00
10.00
87.80
84.50
83.11
81.97
84.3 2.53 1.26 3.00
521
522
523
524
25.00
25.00
25.00
25.00
56.75
48.75
45.75 
51.25
46.00
46.00
44.50
44.50
25.00
25.00
25.00
25.00
88.83
76.31
74.03
82.93
80.5 6.70 3.35 8.32
525
526
0.00
0.00
0.00
0.00
53.30
68.50
2.00
1.00
0.00
0.00
Recovery = 81.5%
ABBREVIATIONS
S.No = Sample number or spike number
Cone of sample = Concentrationof the drug flunixin in the plasma sample in ug/ml 
Std cone = Concentration of standard in ug/ml
Mean % recovery = It is the mean of the percentage recovery of flunixin for each set of spiked samples
Sample std. dev = Sample standard deviation
Sample std. error = Sample standard error of the mean % recovery
% = Percentage '
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C2: Inter-assay coefficient of variation, in the HPLC techniques used for flunixin
analysis, in the 20 trial dogs in the study
This table shows the variation in the % recoveries of the same concentration of spiked 
samples of flunixin, in the 20 different assays performed on the 20 trial dogs, on 20  
different days. An inter-assay coefficient of variation was performed to determine the 
degree of variation in the % recoveries of the spikes, between the 20 different assays 
performed.
Dogs no 1 - 10 (group A) received flunixin, 1.1 mg/kg iv, during anaesthesia, prior to the 
start of surgery
Dogs no 11 - 20 (group B) received flunixin, 1.1 mg/kg iv, immediately after anaesthesia 
terminated
% recovery of each spike, for the individual trial dogs, are filled in the given table
Spike cone 0.25  ug/ml 1 ug/ml 2 ug/ml 5 ug/ml 10 ug/ml 25 ug/ml
Dog 1 73.7 65.5 83.8 87.5 84.7 92.3
Dog 2 86.1 71.3 83.2 78.7 88.7 *
Dog 3 63.9 62.4 61.6 65.2 84.5 79.7
Dog 4 72.3 71.0 68.3 78.2 75.7 85.5
Dog 5 79.1 67.6 75.4 69.8 * 60.2
Dog 6 91.0 83.9 91.3 90.4 79.1 95.9
Dog 7 60.0 73.2 84.9 84.4 95.4 86.3
Dog 8 88.7 90.7 78.4 88.2 95 .0 89.5
Dog 9 111.6 94.6 96.3 93.8 * 88.7
Dog 10 64.5 65.6 78.5 80.0 * 78.8
Dog 11 78.1 87.5 75.6 92.0 98.3 93.1
Dog 12 67.9 72.9 76.1 80.2 * 83.3
Dog 13 86.6 # 72.4 89.4 84.8 67.2
Dog 14 119.0 89.3 81.7 86.8 106.9 90.4
Dog 15 98.5 81.1 76.5 88.2 86.3 79.3
Dog 16 73.1 81.6 83.9 91.2 * 94.5
Dog 17 66.7 65.7 82.6 98.3 86.5 77.5
Dog 18 80.3 * 86.1 74.4 80.2 92.2
Dog 19 73.0 89.5 83.8 95.6 86.1 92.0
Dog 20 64.7 69.2 67.5 * 74.6 93.5
Mean % recovery 79.9 76.8 79.4 84.9 87.1 85.3
Sample std dev 15.9 10.4 8.2 8.8 8.7 9.6
Sample std error 3.6 2.5 1.8 2.0 2.3 2.2
Coeff of var (%) 19,9 13.6 10.3 10.4 10.0 11.2
ABBREVIATIONS
Mean % recovery
Sample std dev 
Sample std error 
Coeff of var (%)
= Mean percentage recovery of drug flunixin for each spike, 
in the 20 different assays performed (Dogs trial No 1 - 20)
= Sample standard deviation 
= Sample standard error
= Coefficient of variance , expressed as a percentage 
= Missing value
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APPENDIX D
TABLES
TABLE D1 - Pharmacokinetic parameters of flunixin, in dogs in group A, obtained after 
compartmental analysis o f data.
TABLE D2 - Pharmacokinetic parameters of flunixin, in dogs in group B, obtained after 
compartmental analysis o f data.
TABLE D3 - Pharmacokinetic parameters o f flunixin, in dogs in group A, obtained after 
non-compartmental analysis o f data.
TABLE D4 - Pharmacokinetic parameters of flunixin, in dogs in group B, obtained after 
non-compartmental analysis o f data.
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Table D l: Pharm acokinetic param eters o f flunixin , obtained after com partm ental analysis o f data, in dogs in group A
(Trial No 1- 10)
Trial No UNITS 1 2 3 4 5 6 7 8 9 10 MEAN SEM
EXPONENTIAL 3 3 3 3 3 2 3 3 3 3
1/2 LIFE P (distribution) hours 0.031 0.038 0.032 0.019 0.053 0.179 0.048 0.039 0.045 0.042 0.05 0.01
1/2 LIFE A (distribution) hours 1.291 0.909 1.16 0.418 0.818 1.376 0.784 0.353 1.011 0.90 0,12
1/2 LIFE B (elimination) hours 9.704 7.727 11.855 4.75 15.398 3.834 9.482 5.763 5.64 4.474 7.86 1 18
CPO ug/ml 35.558 36.614 35.639 39.61 24.098 25.541 29.8 23.6 49.388 34.69 33.45 2.52
AUC ug.hr/ml 37.144 41.39 32.794 44.256 15.361 26.643 47.673 18.38 69.868 48.481 38.20 5.08
AUC ( observed) ug.hr/ml 36.244 38.723 29.293 41.631 14.27 20.31 43.999 16.64 69.628 46.254 35.65 5.24
Vc ml/kg 30.94 30.04 30.87 27.77 45.65 43.07 36.91 46.62 22.27 31.71 34.58 2.58
Vd (ss) ml/kg 148.8 188.8 168.8 150.3 528.9 189.2 166.6 208 111.5 98 195.89 38.5
CL(b) ml/kg. hr 29.6 26.6 33.5 24.9 71.6 41.3 23.1 59.8 15.7 22.7 34.88 5.64
K el /hr 0.957 0.885 1.087 0.895 1.569 0.846 0.625 1.284 0.707 0.716 0.96 0.09
Table D2: Pharmacokinetic parameter of flunixin, obtained after compartmental analysis of data, in dogs in group B 
(Trial No 11- 20)
T ria l No U N ITS 11 12 13 14 15 16 17 18 19 20 MEAN SEM
EXPONENTIAL 3 3 3 3 3 2 3 3 3 3
1/2 LIFE P (distribution) hours 0.02 0.07 0.06 0.04 0.04 1.22 0.03 0.04 0.02 0.06 0.16 0.12
1/2 LIFE A (distribution) hours 0.59 0.74 1.16 0.80 0.62 0.46 0.90 0.57 1.03 0.76 0.08
1/2 LIFE B (elimination) hours 3.76 8.29 9.53 5.64 5.48 5.37 3.59 5.12 4.66 9.58 6 10 0.74
CPO ug/ml 47.43 30.27 36.88 38.52 36.90 15.60 37.27 45.95 35.47 49.55 37.38 3.08
AUC ug. hr/ml 33.52 30.95 46.51 49.97 34.98 38.40 16.13 47.01 21.52 38.23 35.72 3.45
AUC ( observed) ug.hr/ml 31.06 32.22 42.39 46.05 33.14 35.00 15.46 46.27 18.45 33.98 33.40 3.27
Vc ml/kg 23.19 36.34 29.83 28.55 29.81 70.50 29.52 23.94 31.01 22.20 32.49 4.43
Vd (ss) ml/kg 114.90 142.40 141.50 138.60 165.40 113.80 115.90 84.70 180.70 128.40 132.63 8.73
CL(b) ml/kg. hr 32.80 35.50 23.70 22.00 31.40 28.60 68.20 23.40 51.10 28.80 34.55 4-58
K el /hr 1.42 0.98 0.79 0.77 1.06 0.41 2.31 0.98 1.65 1.30 1.16 0.17
ABBREVIATIONS
SEM = Standard error of means
1/2 LIFE P (distribution) =  Distribution half life 
1 /2 LIFE A (distribution) = Distribution half life 
1/2 LIFE B (elimination) = Elimination half life
CPO = Initial concentration o f drug m plasma, following an mtravenous injection
AUC = Area under zero moment curve
AUC ( observed) =  Area under the curve (observed values)
Vc = Apparent volume o f central compartment
Vd (ss) =  Apparent volume o f distribution at steady state
CL(b) = Body clearance o f drug
K el =  Elimination rate constant
Table D3: Flunixin pharmacokinetic variables obtained after non-compartmental analysis o f data, in dogs in group A
(trial no 1-10)
TRIAL NO UNITS 1 2 3 4 5 6 7 8 9 10 MEAN SEM
AUC ( observed) ug.hr/ml 37.59 41.57 31.29 41.86 15.57 21.20 59.68 18.04 78.11 42.20 38.71 6.10
AUMC (observed) ug.hr/ml 168.68 288.29 951.08 266.69 120.04 102.42 737.46 85.22 493.41 134.57 334.79 94.50
MRT hours 4.49 6.94 30.40 6.37 7.71 4.83 12.36 4.72 6.32 3.19 8.73 2.53
Vd (ss) ml/kg 131.31 183.51 1068.56 167.42 544.68 250.67 227.76 288.05 88.96 83.12 303.40 94.80
CL(b) ml/kg.hr 29.26 26.46 35.16 26.28 70.65 51.89 18.43 60.98 14.08 26.07 35.93 5.96
Table D4: Flunixin pharmacokinetic variables obtained after non-compartmental analysis of data, in dogs in group B 
(trial no 11- 20)
TRIAL NO UNITS 11 12 13 14 15 16 17 18 19 20 MEAN SEM
AUC ( observed) ug.hr/ml 31.38 32.86 44.38 47.62 33.37 35.27 20.07 46.55 18.47 35.62 34.61 3.15
AUMC (observed) ug.hr/ml 104.14 126.65 270.35 302.24 179.32 130.30 100.94 163.77 60.19 173.57 161.15 23.90
MRT hours 3.32 3.85 6.09 6.35 5.29 3.69 4.98 3.52 3.26 4.87 4.52 0.36
Vd (ss) ml/kg 116.33 129.02 150.99 146.61 171.86 115.22 270.24 83.14 194.08 150.48 152.80 16.40
CL(b) ml/kg.hr 35.05 33.48 24.79 23.10 32.48 31.19 54.27 23.63 59.56 30.88 34.84 3.93
ABBREVIATION
SEM
AUC ( observed) 
AUMC (observed) 
MRT 
Vd (ss)
CL(b)
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= Standard error o f mean 
= Area under the zero moment curve (observed) 
= Area under the first moment curve (observed) 
= Mean residence time
= Apparent volume of distribution at steady state 
- Body clearance of drug
